CA2129287C - Use of cloprostenol, fluprostenol and their analogues to treat glaucoma and ocular hypertension - Google Patents
Use of cloprostenol, fluprostenol and their analogues to treat glaucoma and ocular hypertension Download PDFInfo
- Publication number
- CA2129287C CA2129287C CA002129287A CA2129287A CA2129287C CA 2129287 C CA2129287 C CA 2129287C CA 002129287 A CA002129287 A CA 002129287A CA 2129287 A CA2129287 A CA 2129287A CA 2129287 C CA2129287 C CA 2129287C
- Authority
- CA
- Canada
- Prior art keywords
- chain
- straight
- compound
- formula
- branched alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 title claims abstract description 22
- 229960004409 cloprostenol Drugs 0.000 title claims abstract description 22
- WWSWYXNVCBLWNZ-QIZQQNKQSA-N fluprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(C(F)(F)F)=C1 WWSWYXNVCBLWNZ-QIZQQNKQSA-N 0.000 title claims abstract description 19
- 229950009951 fluprostenol Drugs 0.000 title claims abstract description 16
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 title claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 91
- 239000000203 mixture Substances 0.000 claims abstract description 85
- 150000002148 esters Chemical class 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 39
- 125000002091 cationic group Chemical group 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 150000001412 amines Chemical group 0.000 claims description 9
- 125000005547 pivalate group Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- OCNSAYQJDKJOLH-AHTXBMBWSA-N propan-2-yl (z)-7-[(1r,2r,3r,5s)-2-[(e,3r)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(Cl)=C1 OCNSAYQJDKJOLH-AHTXBMBWSA-N 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims 25
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 168
- 235000019439 ethyl acetate Nutrition 0.000 description 58
- -1 PGF2a isopropyl ester Chemical class 0.000 description 52
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 50
- 239000000243 solution Substances 0.000 description 42
- 239000010410 layer Substances 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 239000012044 organic layer Substances 0.000 description 27
- 230000004410 intraocular pressure Effects 0.000 description 25
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 229920006395 saturated elastomer Polymers 0.000 description 23
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical class CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 21
- 238000005481 NMR spectroscopy Methods 0.000 description 19
- 206010020565 Hyperaemia Diseases 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 230000009467 reduction Effects 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- 101150041968 CDC13 gene Proteins 0.000 description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 150000003180 prostaglandins Chemical class 0.000 description 12
- 239000002253 acid Substances 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 229940126062 Compound A Drugs 0.000 description 8
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 8
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 8
- 229960000686 benzalkonium chloride Drugs 0.000 description 8
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 8
- 210000000795 conjunctiva Anatomy 0.000 description 8
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 5
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 102100034195 Thrombopoietin Human genes 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 5
- 150000002009 diols Chemical class 0.000 description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940119743 dextran 70 Drugs 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 4
- 235000019799 monosodium phosphate Nutrition 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000282567 Macaca fascicularis Species 0.000 description 3
- 206010030043 Ocular hypertension Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- SXXLKZCNJHJYFL-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[4,5-c]pyridin-5-ium-3-olate Chemical compound C1CNCC2=C1ONC2=O SXXLKZCNJHJYFL-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940009662 edetate Drugs 0.000 description 2
- 229940124274 edetate disodium Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- 229940074439 potassium sodium tartrate Drugs 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- MKPLKVHSHYCHOC-JPVYXPJZSA-N propan-2-yl (e)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3r)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate Chemical compound CC(C)OC(=O)CCC\C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-JPVYXPJZSA-N 0.000 description 2
- 229960003981 proparacaine Drugs 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 230000001179 pupillary effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- OQXSRALAOPBHPM-UHFFFAOYSA-N 2-hydroxypropanoic acid;silver Chemical compound [Ag].CC(O)C(O)=O OQXSRALAOPBHPM-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- HORNXRXVQWOLPJ-UHFFFAOYSA-N 3-chlorophenol Chemical compound OC1=CC=CC(Cl)=C1 HORNXRXVQWOLPJ-UHFFFAOYSA-N 0.000 description 1
- HTYRTGGIOAMLRR-UHFFFAOYSA-N 5-amino-4-hydroxybenzene-1,3-disulfonic acid Chemical compound NC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O HTYRTGGIOAMLRR-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 101100048435 Caenorhabditis elegans unc-18 gene Proteins 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000490229 Eucephalus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101150093156 Rras gene Proteins 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- FYJKEHKQUPSJDH-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;potassium Chemical compound [K].C[Si](C)(C)N[Si](C)(C)C FYJKEHKQUPSJDH-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000262 chemical ionisation mass spectrometry Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 101150087654 chrnd gene Proteins 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- VONWDASPFIQPDY-UHFFFAOYSA-N dimethyl methylphosphonate Chemical compound COP(C)(=O)OC VONWDASPFIQPDY-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- PMOIAJVKYNVHQE-UHFFFAOYSA-N phosphanium;bromide Chemical compound [PH4+].[Br-] PMOIAJVKYNVHQE-UHFFFAOYSA-N 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000003259 prostaglandin group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0025—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups
Abstract
Disclosed is the use of cloprostenol, fluprostenol, their analogues and their pharmaceutically acceptable salts and esters for the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic compositions comprising said compounds.
Description
USE OF CLOPROSTENOL, FI_UPROSTENOL AND THEIR ANALOGUES
TO TREAT GLAUCC>MA AND OCULAR HYPERTENSION
BACKGROUND OF THE INVENTI~N_ The present invention relates to the treatment of glaucoma and ocular hypertension. In particular, the present invention relates to the use of cloprostenol, fluprostenol, their analogues and their pharmaceutically acceptable salts and esters to treat glaucoma and ocular hyyertension.
Cloprostenol and fluprostesnol, both known compounds, are synthetic io analogues of PGF2a, a naturally-occurring F-series prostaglandin (PG).
Structures for PGF2a (I), cloprostenol (II), and fluprostenol (III), are shown below:
~ 7 ~4 ~2 alpha chain g 5 3 C~OH
11 '4 16 18 12 ~ 15 ~20 HO 13 ~ 1~/ X19' m'nega chain OH (I) HO
:,.y/'~./'~'C02H
H~~ _ ~ ~ , OH.
ci (ll) ,,,,~'~/~co2H
'G~~~O
HO OH
cF3 (III) The chemical name for cloprostenol is 16-(3-chlorophenoxy)-17,18,19,20-tetranor PGFza. Monograph No. 2397 (page 375) of The Merck Index, 11 th Edition (1989) describes the preparation and knawn pharmacologiical profiles of cloprostenol. Fluprastenol has the chemical name 16-(3-tnrifluoromethylphenoxy)-17,18,19,20-tetranor PGF2a.
Monograph No. 4121 (pages 656-657) of T~~wtei~rc~ Index, 11th Edition (1989) describes the preparation arid _ known pharmacological profiles of fluprostenol. Claprostenol and fluprostenol are 16-aryloxy PGs and, in addition to the substituted aromatic ring, differ from the io ~ natural product, PGF2a in that an oxygen atom is embedded within the lower (omega) chain. This oxygen interruption forms an ether functionality.
Naturally-occurring prostaglandins are known to lower intraocular pressure (IOP) after topical ocular instillation, Ibut generally cause inflammation, as well as surface irritation characteri;'ed by conjunctiva) hyperemia and edema. Many synthetic prostaglandins halve been observed to lower intraocular pressure, but such compounds also produce the aforementioned side effects, Various methods have been used in attempting to overcome the ocular side effects associated with prostaglandins. Stjernschantz et al. (EP 364 417 A1 ) have synthesized derivatives 20 or analogues of naturally-occurring prostaglandins in arder to design out selectively the undesired side effects while maintaining the IOP-lowering effect. Others, including Ueno et al. (EP 330 511 A2) and Wheeler (EP 435 682 A2) have tried complexing prostaglandins with various cyclodextrins. ' The Stjernschantz et al. publication is of particular interest, as it demonstrates that certain synthetically-modified PGF2a analogues retain the potent IOP-lowering effect of the parent (PGF2a isopropyl ester) while decreasing the degree of conjunctiva) hyperemia. In this publication, the only modification to the PG structure is to the omega chain: the chain length is 4-13 carbon atoms 30 "optionally interrupted by preferably not more than two heteroatoms (O, S, or N)"
and includes a phenyl ring (substituted or unsubstituted) on the terminus (see page 3,. line 44 to page 4, line 7). Stjernschaniiz et al. exemplify two subclasses within this definition:
(1 ) carbon-only omega chains, ~i.e., ', HO,, 14 ' 1s ~Ph HO ' 3 n =1-10 OH
and (2) heteroatom-interrupted omega chains, i.e., HO, ,,,~~~
is n ~~Ph HO '3 off n=1-10 ,o ' In particular, the 17-phenyl-18,'19,20-trinor analogue of PGF2~, isopropyl ester (formula 1, n=2) displayed a superior separation of toward and untoward activities.
Furthermore, the 13,14-dihydro~ analogue of 17-phenyl-18,19,20-trinor PGF2a ,5 i sopropyl ester displayed an even more favorable separation of activities.
Both 17-phenyl PGFza and its 13,14-dihydro congener fall into the former (formula 1, carbon-only omega chain) subl:lass. Additional synthetic analogues employing the phenyl substituent on the end of the omega chain explored the effects of chain elongation, chain contraction, and substitution on the phenyl ring. However, such o analogues showed no apparent therapeutic improvement over the preferred formulation, 13,14-dihydro-17-phenyl-18,19,20-trinor PGF2~ isopropyl ester.
Because they contain h~=teroatom (O) interruption of the omega chain, both cloprostenol and fluprostenol a.re generically included in the subclass defined in 25 formula 2 by Stjernschantz et al. However, neither compound is specifically mentioned by Stjernschantz et al. and the disclosure is primarily related to carbon-only omega chains. The only example of a heteroatom-interrupted omega chain ~L,, disclosed by Stjernschantz et al. is 1fi-phenoxy-17,18,19,20 tetranor PGF2a isopropyl ester (see formula 2, n=1 ). The IOP data revealed by Stjernschantz et al.
for 16-phenoxy-17,18,19,20-tetranor PGF2~ isopropyl ester (see Stjernschantz et al, page 17, Table V) indicate an initial increase in IOP (1-2 hours after administratian) s followed by a decrease. Moreover, this compound displays unacceptable hyperemia (see Stjernschantz ~et al., Table 1V, line 40). In short, data from Stjernschantz et al. demonstrate that the oxygen-interrupted omega chain subgeneric class of compound:; (see formula 2) displays an unacceptable therapeutic profile.
,o :iIJMMAFiY OF THE INVENTIC1N
It has now been unexpectedly found that cloprostenol, fluprostenol, and their ,5 pharmaceutically acceptable ss~lts and esters show significantly greater IOP
reduction than the compounds of Stjernschantz et al., while having a similar or lower side effect profile. In particular, it appears that the addition of a chlorine atom or a trifluoromethyl group to the meta position on the phenoxy ring at the end o~f the omega chain provides a compound having excellent IOP reduction without o the significant side effects found with other, closely related compounds.
In addition, it has also b~,en unexpectedly found that certain novel cloprostenol and fluprostenol analogues are useful in treating glaucoma and ocular hypertension. In particular, topical application of ophthalmic compositions z5 comprising these novel clopros~tenol and fluprostenol analogues result in significant IOP reduction.
TO TREAT GLAUCC>MA AND OCULAR HYPERTENSION
BACKGROUND OF THE INVENTI~N_ The present invention relates to the treatment of glaucoma and ocular hypertension. In particular, the present invention relates to the use of cloprostenol, fluprostenol, their analogues and their pharmaceutically acceptable salts and esters to treat glaucoma and ocular hyyertension.
Cloprostenol and fluprostesnol, both known compounds, are synthetic io analogues of PGF2a, a naturally-occurring F-series prostaglandin (PG).
Structures for PGF2a (I), cloprostenol (II), and fluprostenol (III), are shown below:
~ 7 ~4 ~2 alpha chain g 5 3 C~OH
11 '4 16 18 12 ~ 15 ~20 HO 13 ~ 1~/ X19' m'nega chain OH (I) HO
:,.y/'~./'~'C02H
H~~ _ ~ ~ , OH.
ci (ll) ,,,,~'~/~co2H
'G~~~O
HO OH
cF3 (III) The chemical name for cloprostenol is 16-(3-chlorophenoxy)-17,18,19,20-tetranor PGFza. Monograph No. 2397 (page 375) of The Merck Index, 11 th Edition (1989) describes the preparation and knawn pharmacologiical profiles of cloprostenol. Fluprastenol has the chemical name 16-(3-tnrifluoromethylphenoxy)-17,18,19,20-tetranor PGF2a.
Monograph No. 4121 (pages 656-657) of T~~wtei~rc~ Index, 11th Edition (1989) describes the preparation arid _ known pharmacological profiles of fluprostenol. Claprostenol and fluprostenol are 16-aryloxy PGs and, in addition to the substituted aromatic ring, differ from the io ~ natural product, PGF2a in that an oxygen atom is embedded within the lower (omega) chain. This oxygen interruption forms an ether functionality.
Naturally-occurring prostaglandins are known to lower intraocular pressure (IOP) after topical ocular instillation, Ibut generally cause inflammation, as well as surface irritation characteri;'ed by conjunctiva) hyperemia and edema. Many synthetic prostaglandins halve been observed to lower intraocular pressure, but such compounds also produce the aforementioned side effects, Various methods have been used in attempting to overcome the ocular side effects associated with prostaglandins. Stjernschantz et al. (EP 364 417 A1 ) have synthesized derivatives 20 or analogues of naturally-occurring prostaglandins in arder to design out selectively the undesired side effects while maintaining the IOP-lowering effect. Others, including Ueno et al. (EP 330 511 A2) and Wheeler (EP 435 682 A2) have tried complexing prostaglandins with various cyclodextrins. ' The Stjernschantz et al. publication is of particular interest, as it demonstrates that certain synthetically-modified PGF2a analogues retain the potent IOP-lowering effect of the parent (PGF2a isopropyl ester) while decreasing the degree of conjunctiva) hyperemia. In this publication, the only modification to the PG structure is to the omega chain: the chain length is 4-13 carbon atoms 30 "optionally interrupted by preferably not more than two heteroatoms (O, S, or N)"
and includes a phenyl ring (substituted or unsubstituted) on the terminus (see page 3,. line 44 to page 4, line 7). Stjernschaniiz et al. exemplify two subclasses within this definition:
(1 ) carbon-only omega chains, ~i.e., ', HO,, 14 ' 1s ~Ph HO ' 3 n =1-10 OH
and (2) heteroatom-interrupted omega chains, i.e., HO, ,,,~~~
is n ~~Ph HO '3 off n=1-10 ,o ' In particular, the 17-phenyl-18,'19,20-trinor analogue of PGF2~, isopropyl ester (formula 1, n=2) displayed a superior separation of toward and untoward activities.
Furthermore, the 13,14-dihydro~ analogue of 17-phenyl-18,19,20-trinor PGF2a ,5 i sopropyl ester displayed an even more favorable separation of activities.
Both 17-phenyl PGFza and its 13,14-dihydro congener fall into the former (formula 1, carbon-only omega chain) subl:lass. Additional synthetic analogues employing the phenyl substituent on the end of the omega chain explored the effects of chain elongation, chain contraction, and substitution on the phenyl ring. However, such o analogues showed no apparent therapeutic improvement over the preferred formulation, 13,14-dihydro-17-phenyl-18,19,20-trinor PGF2~ isopropyl ester.
Because they contain h~=teroatom (O) interruption of the omega chain, both cloprostenol and fluprostenol a.re generically included in the subclass defined in 25 formula 2 by Stjernschantz et al. However, neither compound is specifically mentioned by Stjernschantz et al. and the disclosure is primarily related to carbon-only omega chains. The only example of a heteroatom-interrupted omega chain ~L,, disclosed by Stjernschantz et al. is 1fi-phenoxy-17,18,19,20 tetranor PGF2a isopropyl ester (see formula 2, n=1 ). The IOP data revealed by Stjernschantz et al.
for 16-phenoxy-17,18,19,20-tetranor PGF2~ isopropyl ester (see Stjernschantz et al, page 17, Table V) indicate an initial increase in IOP (1-2 hours after administratian) s followed by a decrease. Moreover, this compound displays unacceptable hyperemia (see Stjernschantz ~et al., Table 1V, line 40). In short, data from Stjernschantz et al. demonstrate that the oxygen-interrupted omega chain subgeneric class of compound:; (see formula 2) displays an unacceptable therapeutic profile.
,o :iIJMMAFiY OF THE INVENTIC1N
It has now been unexpectedly found that cloprostenol, fluprostenol, and their ,5 pharmaceutically acceptable ss~lts and esters show significantly greater IOP
reduction than the compounds of Stjernschantz et al., while having a similar or lower side effect profile. In particular, it appears that the addition of a chlorine atom or a trifluoromethyl group to the meta position on the phenoxy ring at the end o~f the omega chain provides a compound having excellent IOP reduction without o the significant side effects found with other, closely related compounds.
In addition, it has also b~,en unexpectedly found that certain novel cloprostenol and fluprostenol analogues are useful in treating glaucoma and ocular hypertension. In particular, topical application of ophthalmic compositions z5 comprising these novel clopros~tenol and fluprostenol analogues result in significant IOP reduction.
i r~=, IgBIFF ~,~~61F'Tl~t~.F THE DRAWINt3, Figure 1 Is a graph showing the rs~iative hyperemia scaraa (cumulative) of five te$ted campounds (see Talala 2, below), two a~ which era compaund$ of the s present lnventivn.
Figure ~ is a graph shpwing the relative IC7P-lowering affects of flue tested oampaunds ($ae Table ~, balaw), two of which era cor~npounds of the present invention. The dose for each a1' the tasted campounds was 0.3 Ng.
Figure 3 is a graph simils~r to that c>f Figure ~, showing relative 1~P-fawering affects of different cancentratlans of A (cloprostenoi, isopropyl ester) and E
(13,14-dit~ydro-17-phenyl-18,1~,~~-trinr,r PU'F2a, Isopropyl ester), 16 ' .G.~TAII.Ed ~? F.~~.C~LG7:~IE1NV~.l~lll~2.d, The oornpounds useful In the present invantian have the following general formula:
..,,,.UFi1 X
.~ ~' ''\
O~i~ ~~
Y
(IV) wherein:
R, a H; C~-Ci2 straight-~hs~in or bre~nched alkyl; C,-C,2 straight-chain ar branched aryl; ~3-C.8 cycioalkyl; a cationic salt moiety; or a pharmaceutically acceptable amine moiety;
R~, R3 = H, or C,-C5 straight-chain or branched alkyl; or R2 and R3 taken together may represent (~;
ty 6' t:;.r;
_ c~~_.~
X = O, S, or CH2;
_-- represents any combination of a single bond, or a cls or traps double bard for the alpha (upper) chain; and a single bond or frees double bond far the omega flowery chain;
R~ ~ H, C,-C,o straight-c~iain or branched alkyl, or C,-C,o straight-chain or branched aryl;
R" - H, ~,-C,o straight-chain ar branched alkyl, or C,-C1U ,straight-chain or branched aryl;
'~ = U; or hl and C7R,~ in either configuration, wherein R,6 = H, C,-C,o str~xight-chain or branched alkyl, or C,-C,n straight-chain or branched aryl;
Z = CI ar f~F3;
with the proviso that when R~ and R3 taken together represent O, then R, ~ C,-C,2 ~' strsright-chaln or branched aryl; and when R2 - i~3 ~ H, then R, ~ a cationic salt 15 moiety or a pharmaceutically acneptable amine moiety, The compounds of the present invention include free acids, alkali and alkaline earth metal salts, ammonium and amine salts, and esters. Preferred Baits are those involving aikali and alkaline earth metal rations, particularly sodium and potassium, and amine Salts, especially the tris(hydroxymethyi)aminamethane ("tramethamine") salts. Praferren esters are C,-C,2 alkyl esters, particularly straight or branched C,-CB alkyl ostgrs, especially methyl, ethyl, isopropyl, cyclopropyl, cyclopropyl methyl, butyl, cyciobutyl, isobutyl, t-butyl or pentyl.
Particularly preferred compounds of formula (IV) Bra the sodium and tromethamlne salts ~R
NaQ, CH3N*(CH2OH)3) and the m~sthyl, isopropyl, and t-butyl eskers (s~ = CH3, Chf (CH3)a~ C(CH3)3), Alkali metal salts and alka'~~Ine earth metal salts may be formed conventionally from the acid form. The acid may ba converted to the 9ster by conventional condensation with an alcohol (e,g., C,-C3 alkyl alcohol) or by reaction with an alkyl electrophile (e.g., C,-C, alkyl iodide) fn the presence of base, _.
according to known procedures, In a simi9ar manner, other esterlflcations may be effected as Is known in the art employing other low alkyl, cycloalkyl, cycloalkyalkyl, aryl, ar arylalkyl alcohols anrflc~r'halides such as i$opropanol, ayalaprapanol, cyclaprapylmethanoi, ar phenyl r~r hanzyl Hir:c~hnl nr InrlirfA. ~inra such esterification reactions era well known, they are net further described here.
Preferred compounds include ciaprastenol isopropyl ester (Table II, compound A), fluprostenol isopropyl ester (compound B), the 3-axe form of cloprostanol Isopropyl aster (Tab'le 1, compound 5), 13,1-dlhydrofluprostenal isopropyl ester (compound 6), cloprostenol-1-0l (compound 'Y), and 13,14-dihydraaloprostenol-1-of pivaloates (compound g).
The campavnd9 of fc~rrttulf~ (IV) are useful in lowering intraocular pressure and thus era useful in the treatment of glaucoma. The preferred route of administration is tapfaal. 'The da,3age range far topical administration is generally between about I~.UU1 and about 1000 micrograms per eys (pgpaya) and Is preferably between about 0.01 acrd about 100 pg/eye and most preferably between about U.US and 10 yglaye. Tha c;ampoundls of the present invention can be administered as solutions, suspensions, or emulsions (dispersions) In a suitable ophthalmic veltlcla.
In forming compositions far topical a.dministratlon, the compounds of the present Invention are gartArally fa~rrriulated as between about O.Ot~00~ to about 3 par~;ant by weight (wt%) solutlon4; In water at a pH between 4.5 to 8Ø The corr~pounds are preferably formulated as between about 0.0003 to about 0.3 wt°/a and, most preferably, between ar~out 0.003 and about 0.03 wt°/o, While the precise regimen Is left to the discretion of the clinician, it Is recommended that the resulting solution ba topically applied by ple~clng one drag irt each eye one or two times a day.
f~~' 1. ~~Y ....
Other ~Ingredi~nts wllch rtlay i~o ('iesirahie tv use Irt the ophthalmic preparations of the present Invention Include preservatives, co-solvents and viscosity building agents, Antlrnicrobla) Pre~~,r t~ Ives,:
C~phthalrnic products arA typrc;erly pgckaged In rrtuitidose form, whlolt generally require the addition of preservatives to prevent rrticrobiai contamination during use, ~ultable preservatives include; benzaikortium chloride, titimerosal, chiorobutanal, methyl parar>sn, propyl paraben, pftenylethyl alcohol, edetate disodium, sorbic acid, (~narner MQ~, or other ager~fs known to those skilled In thg art. such preservatives arsr typically employed at a concentration between about x.001 °/o c~r~rd about 1.0% by weight.
Co-~oivent~:
Prostaglandlns, end ;particularly ester derivatives, kypleelly Rave limited solubility fn water and tf~erefc~re stay require a surfactant or athAr appropriate co-solvent in the composition, Suah ro-solvants Include; t'olysorbat~ 20, r30 and 80;
F'luronic~ F-88, F-8d and P-1 C~;~; Tyloxepolrlb; ~remophor~ EI_, sodium dodecyl sulfate; glycerol; P~Q d04; propylene glycol; cycladextrins; or other agents known a!o to those skilled In the art. ~3uch co-solvents are typically employed at a concentration between about Q.01 % and about ~b/o by weight.
Y1.~~.c.~_I~g n ~;
Viscosity greater than that of simple aqueous $olutlons may be desirable to Increase ocular absorption of the active compound, to decrease variability in dispensing the formulations, to decrease physical separation of cornpanents of a suspension or emulsion of f~ormulatlon and/or otherwise to Improve the c~phthalrrila formulation. such viscosity building agents Include, far exarrtple, polyvinyl airat7oi, polyvinyl pyrrolidone, rnethy! cellulose, hydroxy propyl methylcellulase, hyrir~~xyett~yl i r ~.
ce0lulose, car'ty. c~xymethyl ceilulos>e, hydroxy propyi eellulos~ or other agents known to those skliled fn the art. Such agents are typloa9ly employed at a concentration batween about O.Oi % and about 2% by weight.
Tebie 1 ' aeeaw~n,s CUMPOUND NAME: CC9MPOl~ND ~TRUCTUIgE
~-oxecloprostenoi Isopropyl Ho ester ~.~ ,,,~~°'--o--~'~-co2--Hc3 off ~ 13,14-dihydrofiuprostenol Ho isopropyl ester ,,,,~~'~~,~-""~--~'"'-Cc~p-HO OH
T cloprostenol-1-of ,,tv''~~'"~..~''...'~,OH
Hc7~l off 8 1 x,14-dihydrocloprostenol-1-of Ho w .r o' pivaloate ~,,~~-~.~~wV..~-~...~,,~, W' HO O
OH
GI
~3 ~j ~ i !n the examples below, the following standard abbreviations are used: g =
grams (mg = milligrams); mol := moles (rnmol = millimoles); mol% = mole percent;
mL = milliliters; mm Hg = millirneters of mercury; mp = melting point; by =
boiling point; h = hours; and min = minutes. In addition, "NMR" refers to nuclear magnetic resonance spectroscopy and "CI MS" refers to chemical ionization mass spectrometry.
~
~' ~a ;
~r' EXAMPLE 1: Synthesws of 3-Oxaclop~oster~ol (5) a c~ ci ~ ~ °" ~~"o~.co,Et ' ~ ~ p~P~°~'~
o to tt O
~~'l~p ~ o o f ago o " ci - T ----~-O
011 ~ 011 a a 14 if I
f~oH
( 0 ~~ THPO ~~ THPO
a a is t7 Et~ )wlO~a Et~SIO :~..J
(~Y~(of~aM~
~/u~~~O _ ~~~0 ao THPd ~ 1HPQ
a a a a g~°~~~y~~, n~ea~ ~~ ~ ,f.iao a of na~ nia~ na~o IHPo J! ~ ~4 a , C, G ~ ~", r~ ~
A° Eth~ri {3-chlorophenoxy~~cetate (10~
Acetone (320 ml), 75 g (450 mmol) of ethyl bromoacetate, and 40.0 g (310 mmol) of 3-chlorophenol were mixed together, then 69.8 g (505 mmol) of potassium carbonate was added. The mixture was mechanically stirred and heated s to reflux for 4 h, and after cooling to room temperature, was poured into 350 mL of ethyl acetate. To this was then cautiouslyr added 400 mL of 1 M HCI, taking care to avoid excess foaming. The layers were separated and the aqueous layer was extracted with portions of ethyl acetate (3 X 200 mL). The combined organic layers were dried over MgS04, filtered;, concentrated, and the resulting solid was ,o recrystallized from hexane to af?ford 58 g (87%) of 10 as a white solid, m.p. _ 39-40°C. 'H NMR S 7.20-7.08 (m, 1 H), 8.95-6.82 (m, 2 H), 6.75-6.70 (m, 1 H), 4.53 (s, 2 H), 4.21 {q, J = 7.2 Hz, 2 H), 1.23 (t, J = 7.2 Hz, 3 H).
B: Dimethyrl ~3~- 3-chlor~ghencz -2- x ~~~~rllahosi~honate X11) ,s To 20.6. g (166 mmol, 238 mol%) of dimethyl methylphosphonate in 110 mL
of THF at -78 °C was added drc>pwise 65 mL (162 mmol, 232 mol%) of a 2.5 M
solution of n-BuLi in hexanes. a4fter addition was Complete, the mixture was stirred for an additional 1 h, after which 15.0 g (69.9 mmol) of aryloxyester 10 in 40 mL of THF was added dropwise. The reaction was stirred for 1 h and then quenched by zo the addition of 100 mL of saturated NH~CI. The mixture was poured into 200 mL of a 111 mixture of saturated NaCl,/ethyl acetate, layers were separated, and the aqueous layer was further extracted with ethyl acetate (2 X 100 mL). Combined arganic layers were dried over MgS04, filtered, and concentrated, to afford 20.5 g (100%) of 11 as a viscous ail. 'H NMR ~ 7.22 (t, J = 8.1 Hz, 1 H), 7.05-6.90 (m, 2 25 H), 6.85-6.78 (m, 1 H), 4.72 (s, 2 H), 3.84 (s, 3 H), 3.78 (s, 3 H), 3.27 {d, J = 22.8 Hz, 2 H).
C;.-(3aR 4R 5R SaS,-~5-l,Benz:ovlox~-4~-[(E)-4-~(3-chloro~henoxy)-3-oxo-1-butenvfl-hexah~dro-2H-c5/Clopenta~[b]furan-2- ne X13) Phosphonate 11 (20.5 g,, 70.0 mmol), 2.6 g (62 mmol) of LiCI, and 200 mL
of THF were mixed together at 0 °C and 6.10 g (60.4 mmol) of NEt3 was added.
Aldehyde 12 (14.0 g, 51.1 mmol) dissolved in 50 mL of CH2C12 was then added dropwise. After 1 h, the reaction was poured into 200 mL of a 1/1 mixture of saturated NH~CI/ethyl acetate, 1fie layers were separated, and the aqueous layer was extracted with ethyl acetatE~ (2 X 100 mL). Combined organic layers were dried over MgS(~4, filtered, concentrated, and the residue was chromatographed on ,o silica gel eluting with ethyl acet:atelhexanes, 3/2, to afford 16.2 g (72%) of 13 as a white crystalline solid, m.p. = 101.0-102.0 °C. 'H NMR 8 8.0-7.9 (m, 2 H), 7.62-7.52 (m, 1 H), 7.50-7.38 (m, 2 I-I), 7.18 (t, J = 8.2 Hz, 1 H), 7.0-fi.82 (m, 3 H), 6.75-6.70 {m, 1 H), 6.54 (d, J = 15.1 Hz, 1 H), 5.32 (q, J = 6.2 Hz, 1 H), 5.12-5.05 (m, 1 H), 4.66 (s, 2 H), 3.0-2.8 (m, 3 H), 2.7-2.2 {m, 3 H).
,s ~: ~3aR 4R 5R 6aS)-5-(,Benzovloxvl-4-((E)-(3R)-~3-chloro henoxy;h,3-h~rdrox,, b4~ten~rll-hexahydro-2H cycloaenta[b]fu ran-2-~n 14 To a solution of 9.70 g (22.0 mmol) of enone 13 in 60 mL of THF at -23 °C
was added dropwise a solution of 11.1 g (34.6 mmol of (-)-B-chlorodiisopino-2o campheylborane in 30 mL of ThiF. After 4 h, the reaction was quenched by the dropwise addition of 5 mL of mE=thanol and then warmed to room temperature.
After pouring into 200 mL of a 2/1 mixtures of ethyl acetate/saturated NH4CI, the layers were separated, and the aqueous phase was extracted with ethyl acetate (2 X 100 mL). Combined organic layers were dried over MgS04, filtered, 2s concentrated, and the residue was chromatographed on silica gel eluting with ethyl acetate/hexanes, 3/2, to afford 4.7 g (48°/',) of 14 as a white solid, m. p. 101.0-102.5 °C. 'H NMR 8 8.05-7.95 (m, 2 H), '7.62-7.40 (m, 3 H), 7.18 (t, J
= 8.0 Hz, 1 H), 7.0-6.92 (m, 1 H), 6.85 (t, J = 2.1 Hz, 1 H), 6.77-6.70 (m, 1 H), 5.85 (d of d, J =
Figure ~ is a graph shpwing the relative IC7P-lowering affects of flue tested oampaunds ($ae Table ~, balaw), two of which era cor~npounds of the present invention. The dose for each a1' the tasted campounds was 0.3 Ng.
Figure 3 is a graph simils~r to that c>f Figure ~, showing relative 1~P-fawering affects of different cancentratlans of A (cloprostenoi, isopropyl ester) and E
(13,14-dit~ydro-17-phenyl-18,1~,~~-trinr,r PU'F2a, Isopropyl ester), 16 ' .G.~TAII.Ed ~? F.~~.C~LG7:~IE1NV~.l~lll~2.d, The oornpounds useful In the present invantian have the following general formula:
..,,,.UFi1 X
.~ ~' ''\
O~i~ ~~
Y
(IV) wherein:
R, a H; C~-Ci2 straight-~hs~in or bre~nched alkyl; C,-C,2 straight-chain ar branched aryl; ~3-C.8 cycioalkyl; a cationic salt moiety; or a pharmaceutically acceptable amine moiety;
R~, R3 = H, or C,-C5 straight-chain or branched alkyl; or R2 and R3 taken together may represent (~;
ty 6' t:;.r;
_ c~~_.~
X = O, S, or CH2;
_-- represents any combination of a single bond, or a cls or traps double bard for the alpha (upper) chain; and a single bond or frees double bond far the omega flowery chain;
R~ ~ H, C,-C,o straight-c~iain or branched alkyl, or C,-C,o straight-chain or branched aryl;
R" - H, ~,-C,o straight-chain ar branched alkyl, or C,-C1U ,straight-chain or branched aryl;
'~ = U; or hl and C7R,~ in either configuration, wherein R,6 = H, C,-C,o str~xight-chain or branched alkyl, or C,-C,n straight-chain or branched aryl;
Z = CI ar f~F3;
with the proviso that when R~ and R3 taken together represent O, then R, ~ C,-C,2 ~' strsright-chaln or branched aryl; and when R2 - i~3 ~ H, then R, ~ a cationic salt 15 moiety or a pharmaceutically acneptable amine moiety, The compounds of the present invention include free acids, alkali and alkaline earth metal salts, ammonium and amine salts, and esters. Preferred Baits are those involving aikali and alkaline earth metal rations, particularly sodium and potassium, and amine Salts, especially the tris(hydroxymethyi)aminamethane ("tramethamine") salts. Praferren esters are C,-C,2 alkyl esters, particularly straight or branched C,-CB alkyl ostgrs, especially methyl, ethyl, isopropyl, cyclopropyl, cyclopropyl methyl, butyl, cyciobutyl, isobutyl, t-butyl or pentyl.
Particularly preferred compounds of formula (IV) Bra the sodium and tromethamlne salts ~R
NaQ, CH3N*(CH2OH)3) and the m~sthyl, isopropyl, and t-butyl eskers (s~ = CH3, Chf (CH3)a~ C(CH3)3), Alkali metal salts and alka'~~Ine earth metal salts may be formed conventionally from the acid form. The acid may ba converted to the 9ster by conventional condensation with an alcohol (e,g., C,-C3 alkyl alcohol) or by reaction with an alkyl electrophile (e.g., C,-C, alkyl iodide) fn the presence of base, _.
according to known procedures, In a simi9ar manner, other esterlflcations may be effected as Is known in the art employing other low alkyl, cycloalkyl, cycloalkyalkyl, aryl, ar arylalkyl alcohols anrflc~r'halides such as i$opropanol, ayalaprapanol, cyclaprapylmethanoi, ar phenyl r~r hanzyl Hir:c~hnl nr InrlirfA. ~inra such esterification reactions era well known, they are net further described here.
Preferred compounds include ciaprastenol isopropyl ester (Table II, compound A), fluprostenol isopropyl ester (compound B), the 3-axe form of cloprostanol Isopropyl aster (Tab'le 1, compound 5), 13,1-dlhydrofluprostenal isopropyl ester (compound 6), cloprostenol-1-0l (compound 'Y), and 13,14-dihydraaloprostenol-1-of pivaloates (compound g).
The campavnd9 of fc~rrttulf~ (IV) are useful in lowering intraocular pressure and thus era useful in the treatment of glaucoma. The preferred route of administration is tapfaal. 'The da,3age range far topical administration is generally between about I~.UU1 and about 1000 micrograms per eys (pgpaya) and Is preferably between about 0.01 acrd about 100 pg/eye and most preferably between about U.US and 10 yglaye. Tha c;ampoundls of the present invention can be administered as solutions, suspensions, or emulsions (dispersions) In a suitable ophthalmic veltlcla.
In forming compositions far topical a.dministratlon, the compounds of the present Invention are gartArally fa~rrriulated as between about O.Ot~00~ to about 3 par~;ant by weight (wt%) solutlon4; In water at a pH between 4.5 to 8Ø The corr~pounds are preferably formulated as between about 0.0003 to about 0.3 wt°/a and, most preferably, between ar~out 0.003 and about 0.03 wt°/o, While the precise regimen Is left to the discretion of the clinician, it Is recommended that the resulting solution ba topically applied by ple~clng one drag irt each eye one or two times a day.
f~~' 1. ~~Y ....
Other ~Ingredi~nts wllch rtlay i~o ('iesirahie tv use Irt the ophthalmic preparations of the present Invention Include preservatives, co-solvents and viscosity building agents, Antlrnicrobla) Pre~~,r t~ Ives,:
C~phthalrnic products arA typrc;erly pgckaged In rrtuitidose form, whlolt generally require the addition of preservatives to prevent rrticrobiai contamination during use, ~ultable preservatives include; benzaikortium chloride, titimerosal, chiorobutanal, methyl parar>sn, propyl paraben, pftenylethyl alcohol, edetate disodium, sorbic acid, (~narner MQ~, or other ager~fs known to those skilled In thg art. such preservatives arsr typically employed at a concentration between about x.001 °/o c~r~rd about 1.0% by weight.
Co-~oivent~:
Prostaglandlns, end ;particularly ester derivatives, kypleelly Rave limited solubility fn water and tf~erefc~re stay require a surfactant or athAr appropriate co-solvent in the composition, Suah ro-solvants Include; t'olysorbat~ 20, r30 and 80;
F'luronic~ F-88, F-8d and P-1 C~;~; Tyloxepolrlb; ~remophor~ EI_, sodium dodecyl sulfate; glycerol; P~Q d04; propylene glycol; cycladextrins; or other agents known a!o to those skilled In the art. ~3uch co-solvents are typically employed at a concentration between about Q.01 % and about ~b/o by weight.
Y1.~~.c.~_I~g n ~;
Viscosity greater than that of simple aqueous $olutlons may be desirable to Increase ocular absorption of the active compound, to decrease variability in dispensing the formulations, to decrease physical separation of cornpanents of a suspension or emulsion of f~ormulatlon and/or otherwise to Improve the c~phthalrrila formulation. such viscosity building agents Include, far exarrtple, polyvinyl airat7oi, polyvinyl pyrrolidone, rnethy! cellulose, hydroxy propyl methylcellulase, hyrir~~xyett~yl i r ~.
ce0lulose, car'ty. c~xymethyl ceilulos>e, hydroxy propyi eellulos~ or other agents known to those skliled fn the art. Such agents are typloa9ly employed at a concentration batween about O.Oi % and about 2% by weight.
Tebie 1 ' aeeaw~n,s CUMPOUND NAME: CC9MPOl~ND ~TRUCTUIgE
~-oxecloprostenoi Isopropyl Ho ester ~.~ ,,,~~°'--o--~'~-co2--Hc3 off ~ 13,14-dihydrofiuprostenol Ho isopropyl ester ,,,,~~'~~,~-""~--~'"'-Cc~p-HO OH
T cloprostenol-1-of ,,tv''~~'"~..~''...'~,OH
Hc7~l off 8 1 x,14-dihydrocloprostenol-1-of Ho w .r o' pivaloate ~,,~~-~.~~wV..~-~...~,,~, W' HO O
OH
GI
~3 ~j ~ i !n the examples below, the following standard abbreviations are used: g =
grams (mg = milligrams); mol := moles (rnmol = millimoles); mol% = mole percent;
mL = milliliters; mm Hg = millirneters of mercury; mp = melting point; by =
boiling point; h = hours; and min = minutes. In addition, "NMR" refers to nuclear magnetic resonance spectroscopy and "CI MS" refers to chemical ionization mass spectrometry.
~
~' ~a ;
~r' EXAMPLE 1: Synthesws of 3-Oxaclop~oster~ol (5) a c~ ci ~ ~ °" ~~"o~.co,Et ' ~ ~ p~P~°~'~
o to tt O
~~'l~p ~ o o f ago o " ci - T ----~-O
011 ~ 011 a a 14 if I
f~oH
( 0 ~~ THPO ~~ THPO
a a is t7 Et~ )wlO~a Et~SIO :~..J
(~Y~(of~aM~
~/u~~~O _ ~~~0 ao THPd ~ 1HPQ
a a a a g~°~~~y~~, n~ea~ ~~ ~ ,f.iao a of na~ nia~ na~o IHPo J! ~ ~4 a , C, G ~ ~", r~ ~
A° Eth~ri {3-chlorophenoxy~~cetate (10~
Acetone (320 ml), 75 g (450 mmol) of ethyl bromoacetate, and 40.0 g (310 mmol) of 3-chlorophenol were mixed together, then 69.8 g (505 mmol) of potassium carbonate was added. The mixture was mechanically stirred and heated s to reflux for 4 h, and after cooling to room temperature, was poured into 350 mL of ethyl acetate. To this was then cautiouslyr added 400 mL of 1 M HCI, taking care to avoid excess foaming. The layers were separated and the aqueous layer was extracted with portions of ethyl acetate (3 X 200 mL). The combined organic layers were dried over MgS04, filtered;, concentrated, and the resulting solid was ,o recrystallized from hexane to af?ford 58 g (87%) of 10 as a white solid, m.p. _ 39-40°C. 'H NMR S 7.20-7.08 (m, 1 H), 8.95-6.82 (m, 2 H), 6.75-6.70 (m, 1 H), 4.53 (s, 2 H), 4.21 {q, J = 7.2 Hz, 2 H), 1.23 (t, J = 7.2 Hz, 3 H).
B: Dimethyrl ~3~- 3-chlor~ghencz -2- x ~~~~rllahosi~honate X11) ,s To 20.6. g (166 mmol, 238 mol%) of dimethyl methylphosphonate in 110 mL
of THF at -78 °C was added drc>pwise 65 mL (162 mmol, 232 mol%) of a 2.5 M
solution of n-BuLi in hexanes. a4fter addition was Complete, the mixture was stirred for an additional 1 h, after which 15.0 g (69.9 mmol) of aryloxyester 10 in 40 mL of THF was added dropwise. The reaction was stirred for 1 h and then quenched by zo the addition of 100 mL of saturated NH~CI. The mixture was poured into 200 mL of a 111 mixture of saturated NaCl,/ethyl acetate, layers were separated, and the aqueous layer was further extracted with ethyl acetate (2 X 100 mL). Combined arganic layers were dried over MgS04, filtered, and concentrated, to afford 20.5 g (100%) of 11 as a viscous ail. 'H NMR ~ 7.22 (t, J = 8.1 Hz, 1 H), 7.05-6.90 (m, 2 25 H), 6.85-6.78 (m, 1 H), 4.72 (s, 2 H), 3.84 (s, 3 H), 3.78 (s, 3 H), 3.27 {d, J = 22.8 Hz, 2 H).
C;.-(3aR 4R 5R SaS,-~5-l,Benz:ovlox~-4~-[(E)-4-~(3-chloro~henoxy)-3-oxo-1-butenvfl-hexah~dro-2H-c5/Clopenta~[b]furan-2- ne X13) Phosphonate 11 (20.5 g,, 70.0 mmol), 2.6 g (62 mmol) of LiCI, and 200 mL
of THF were mixed together at 0 °C and 6.10 g (60.4 mmol) of NEt3 was added.
Aldehyde 12 (14.0 g, 51.1 mmol) dissolved in 50 mL of CH2C12 was then added dropwise. After 1 h, the reaction was poured into 200 mL of a 1/1 mixture of saturated NH~CI/ethyl acetate, 1fie layers were separated, and the aqueous layer was extracted with ethyl acetatE~ (2 X 100 mL). Combined organic layers were dried over MgS(~4, filtered, concentrated, and the residue was chromatographed on ,o silica gel eluting with ethyl acet:atelhexanes, 3/2, to afford 16.2 g (72%) of 13 as a white crystalline solid, m.p. = 101.0-102.0 °C. 'H NMR 8 8.0-7.9 (m, 2 H), 7.62-7.52 (m, 1 H), 7.50-7.38 (m, 2 I-I), 7.18 (t, J = 8.2 Hz, 1 H), 7.0-fi.82 (m, 3 H), 6.75-6.70 {m, 1 H), 6.54 (d, J = 15.1 Hz, 1 H), 5.32 (q, J = 6.2 Hz, 1 H), 5.12-5.05 (m, 1 H), 4.66 (s, 2 H), 3.0-2.8 (m, 3 H), 2.7-2.2 {m, 3 H).
,s ~: ~3aR 4R 5R 6aS)-5-(,Benzovloxvl-4-((E)-(3R)-~3-chloro henoxy;h,3-h~rdrox,, b4~ten~rll-hexahydro-2H cycloaenta[b]fu ran-2-~n 14 To a solution of 9.70 g (22.0 mmol) of enone 13 in 60 mL of THF at -23 °C
was added dropwise a solution of 11.1 g (34.6 mmol of (-)-B-chlorodiisopino-2o campheylborane in 30 mL of ThiF. After 4 h, the reaction was quenched by the dropwise addition of 5 mL of mE=thanol and then warmed to room temperature.
After pouring into 200 mL of a 2/1 mixtures of ethyl acetate/saturated NH4CI, the layers were separated, and the aqueous phase was extracted with ethyl acetate (2 X 100 mL). Combined organic layers were dried over MgS04, filtered, 2s concentrated, and the residue was chromatographed on silica gel eluting with ethyl acetate/hexanes, 3/2, to afford 4.7 g (48°/',) of 14 as a white solid, m. p. 101.0-102.5 °C. 'H NMR 8 8.05-7.95 (m, 2 H), '7.62-7.40 (m, 3 H), 7.18 (t, J
= 8.0 Hz, 1 H), 7.0-6.92 (m, 1 H), 6.85 (t, J = 2.1 Hz, 1 H), 6.77-6.70 (m, 1 H), 5.85 (d of d, J =
6.2, 15.5 Hz, 1 H), 5.72 (d of d, J = 4.5, 15.5 Hz, 1 H), 5.30 (q, J = 5.8 Hz, 1 H), so 5.12-5.04 (m, 1 H), 4.58-4.48 (m, 1 H), 3.92 (d of d, J = 3.5, 9.3 Hz, 1 H), 3.80 (d of d, J = 7.3, 9.4 Hz, 1 H), 2.9-2.2 (m, 8 hi).
~~.~'' E.: y3aR.4R. 5R.'6aS~-4-[(E)-(3R)-~3-ChIarQ h~~ enoxy~-3-(tetrahvdrop,~n-2-r~lox~-1-butenyll-hexahydro-~ (tetrahvdrvpyran-2-yrlox),Cap-2H-c)~cloaenta(~lfuran-2-one (16~
To a mixture of 5.1 g (11.5 mmol) of 14 in 200 mL of methanol was added 11.7 g (12 mmol) of K2C03. After 1 h, the mixture was poured into 100 mL of 0.5 P~1 HCI and extracted with ethyl acetate (3 X 100 mL). The combined organic layers were washed successively with water (2 X 100 mL) and saturated NaCI (2 X
100 mL). The organic layer was dried over MgSO4, filtered, and concentrated to afford 4.85 g of crude diol 15, °uvhich was used in the next step without further purification.
,o To a mixture of 4.85 g of crude 15 and 2.4 g (28 mmol) of 3,4-dihydro-2H-pyran in 75 mL of CH2C12 at 0 "C was added 370 mg (1.9 mmol) of p-toluenesulfonic acid monohydrate. After stirring for 45 min, the reaction was poured into 40 mL of saturated NaHCO3, layers were separated, and the aqueous layer was extracted with CH2C12 (2 X 40 mL). The combined organic layers were ,s dried over MgSO~, filtered, and concentrated. The residue was chromatographed an silica gel eluting with 40% ethyl acetate in hexanes, to afford 6.0 g (100%) of 1G
as an oil. ' H NM R (CDC13) 8 (characteri stic peaks only) 7.25-7. i 4 (m, 1 H), 6.95-~i.87 (m, 2 H), 6.83-6.72 (m, 1 H), 5.8-5.4 (m, 4 H), 5.1-4.8 (m, 2 H).
zo _F~~13~-(9S. 11 R~15R_~:11 15_Bis(i.etrahydropyran-2-yrlo_x)~) =16-~~3-chlor~c ~hPnoxv)-2.3.4,5.~.17.18.19.20-nc~nanor-9-trieth~lsila~lox5r-l3~rr~steng~~riethXl~il)~th~r (18) To a suspension of 400 mg (10.5 mmol) of lithium aluminum hydride in 20 rnL of THF at 0 °C was added dropwise a solution of 4.5 g (8.8 mural) of lactone 1~ 6 in 20 mL of THF. After 1 h at 0 °C the mixture was cautiously poured into 100 s rnL of a 1/1 mixture of ice-cold saturated NH4CI/ethyl acetate. The layers were separated, and the aqueous layer was extracted with ethyl acetate (2 X 50 mL).
l'he combined organic layers were dried over MgSO~, filtered, and concentrated to afford 4.5 g (100%) of diol 17 ~Nhich was used in the next step without further purification.
30 ' Triethylsilyl chloride (3.0 g, 20 mmol) was added to a mixture of 4.5 g (8.8 rnmol) of crude 17, 40 mL of DMF, 1.85 g (27.0 mmol) of imidazole, and 310 mg (2.5 mmol) of 4-(dimethylamino)pyridine. After 2 h, the reaction was poured into 1100 mL of a 1/1 mixture of ethyl acetate/saturated NH4C1, layers were separated, s and the aqueous layer was extracted with ethyl acetate (2 X 25 mL). The combined organic layers were washed with water (3 X 25 mL), dried over MgS04, and concentrated. The residue was chromatographed on silica gel eluting with 20% ethyl acetate in hexane to afford 5.2 g (80%) of i8. 'H NMR (CDC13) 8 ' (,characteristic peaks only) 7.22-7.12 (m, 1 H), 6.95-6.88 (m, 2 H), 6.83-6.71 (m, 1 ,o H), 5.8-5.4 (m, 4 H), 5.1-4.8 (m, 2 H), 1.0-0.85 (m, 18 H), 0.7-0.5 (m, 12 H).
c~~l3E]-l9S 11 R 15R)-11 l~Bi r hy~ro~yran-2-vlox~~-16- 3-chloroohenoxv)-a~ 4 5 6.17.18.19.20-nonanor-~-triethyl_silvlox) -~ 13- rp ostP~nal (191 To a mixture of 1.6 g (12.6 mmol)~ of oxalyl chloride and 15 mL of CH2C12 at ,5 -78 °C was added dropwise a solution of 1.54 g (19.7 mmol) of DMSO
in 2 mL of GH2Clz . After 10 min, 4.6 g (fi.2 mmol) of bissilane 18 in 8 mL of CH2C12 was .added dropwise. After 95 min, 3.0 g (30 mmol) of NEt3 was added. The mixture was then warmed to room temperature ;and poured into 70 mL of saturated NH4C1.
The solution was extracted with of CH2GI2 ( 3 X 70 mL) and the combined organic zo Ilayers were dried over MgS04, filtered, <~nd concentrated. The residue was chromatographed on silica gel eluting with 20% ethyl acetate in hexane to afford 2.06 g (53%) of 19 as well as 1.5 g (26%) recovered 18. 'H NMR (CDC13) 8 (characteristic peaks only) 9.78 (t, J = 1.4 Hz, 1 H), 7.22-7.12 (m, 1 H), 6.95-6.88 (m, 2 H), 6.83-6.71 (m, 1 H), fi.8-5.4 (m, 4 H) 5.1-4.8 (m, 2 H), 1.0-0.85 (m, 18 H), 2s 0.7-0.5 (m, 12 H).
H-(,~Z 13E~j9S 11 R 15R)-11-15-Bid(tetrahydrol~s,Lan-2~yrlQxy)-1~3-chloro-I henoxy)-2.3 4.17 18 19 20-he~ptanor-9-triethylsilyloxv-5.13-arostadienoic acid ~nethyrl est r 21 To a solution of 1.35 g (4.24 mmol} of phosphonate 20 and 2.60 g (9.84 s mmol) of 18-crown-6 in 20 mL of THF at -78 °C was added dropwise 6.9 mL (3.45 mmol) of a 0.5 M solution in toluene of potassium hexamethyldisilazane. After stirring for 15 min, a solution of 1.65 g (2.64 mmol) of aldehyde 19 in 20 mL
of THF was added dropwise. One hour later, the mixture was poured into 100 mL of saturated NH4CI/ethyl acetate, 1/1, layers were separated, and the aqueous layer ,o eras extracted with ethyl acetaite (3 X 30 mL). The combined organic layers were dried over MgS04, filtered, concentrated and the residue was chromatographed on silica gel eluting with 20% ethyl acetate in hexane to afford 1.135 g (63%) of 21.
'H NMR (CDC13) S (characteristic peaks only) 7.22-7.11 (m, 1 H), 6.97-6.86 (m, H), 6.85-6.75 (m, 1 H), 6.4-6.2 (m, 1 H), 5.8-5.32 (m, 3 H), 3.66 (s, 3 H).
I: (5Z. l3Ey-(9S 11 R, 1581-1'I .15-Bi,~hv ro~yrran-2-a IoC~yr)~-16-~w3-chloro-phenox~C)-2 3.4 17 18 19 20-heatanor-9-triethylsilyi_ox< -~ 5 13_l~rostadien-1-of X221 To a solution of 850 mg (1.25 mmol) of ester 21 in 10 mL of THF at 0 °C
was added 2.4 mL (3.6 mmol) of a 1.5 M solution in toluene of diisobutylaluminum 2o hydride. After 1 h, the mixture was poured into 20 mL of saturated NHbCI
and was extracted with ethyl acetate (3 X 20 mL). Combined organic layers were dried over MgS04, filtered, and concentrated down to 800 mg (98%) of 22 as an oil. 'H NMR
(CDCI3) 8 (characteristic peaks only) 7.25-7.15 (m, 1 H), 6.97-6.90 (m, 2 H), 6.86-6.75 (m, 1 H), 5.81-5.41 (m, 4 H).
,~!~ l5Z l3El~9S 11 R 15F~-1'~-Bis(tetrahydro~yran-2-yl~i,~ 16-~(~'~-chloro hp enox)C~.-53-ox -a 17 18,19 20-teit~nQr-9-triethylsilyloxy-5 13-pr~~dienoictacid ~~~rol~arl ester l23) To a solution of 415 mg (6.37 mmol) of alcohol 22 in 4 mL of THF at -78 °C
so ~rras added dropwise 0.35 mL (0.87 mol) of a 2.5 M solution in hexane of n-BuLi.
After 15 min, this solution was transferred via syringe to a -78 °C
solution of 195 img (1.08 mmol) of isopropyl bromoacetate in 2 mL of THF. The mixture was kept at -78 °C for 40 min, warmed to room temperature overnight, and then poured into 20 mL of a 1/1 mixture of saturated NH4CI/ethyl acetate. Layers were separated, and the aqueous layer was extracted with ethyl acetate ( 2 X 10 mL). The s combined organic layers were dried over MgSOa, filtered, concentrated, and the c~esidue was chromatographed on silica gel (20% ethyl acetate in hexane) to afford 242 mg (53%) of 23 as an oil. 'H NMR (CDC13) 8 (characteristic peaks only) 7.24-7.15 (m, 1 H), 6.97-6.90 (m, 2 H), 6.86-6.75 (m, 1 H), 5.81-5.41 (m, 4 H), 1.57 (d, J
_. 5.7 Hz, 6 H). ' ,o fC: ~(5ZL13~-1,9S 11 R 15~ 16-(3-ChIQr9~henox,r)-3-oxa-17 18 1 ~ ~0-t r r-~l 11 15-i~rih~rdroy -5 13 ros ~clienoic ~~d isopro~~yr_~~,S~,Q~"~,~, To a solution of 230 mg (0.32 mmol) of silane 23 in 5 mL of THF at room temperature was added 0.33 rroL (0.33 mmol) of a 1 M solution of Bu4NF in THF.
,s After 20 min, the reaction was poured into 4 mL of saturated NH4C1 and was extracted with ethyl acetate (4 X 5 mL). The combined organic layers were dried over MgS04, filtered, concentre~ted, and the residue was chromatographed on silica gel (ethyl acetate/hexane, 1/1 ), to afford 126 mg (65%) of desilylated compound 2.4.
2o To 120 mg of 24 in 5 ml_ of methanol was added 0.4 mL of 2 M HCI. After 1 h, the mixture was added to :3 mL of saturated NaHC03, and the resulting mixture was extracted with ethyl acetate (3 X 8 mL). Combined organic layers ' were dried over MgS04, filtered, concentrated. The resulting residue was then chromatographed on silica gel eluting with ethyl acetate to afford 54 mg (56%) of 5.
2s '3C NMR (CDC13) & 169.92 (C), 159.26 (C), 135,13 (CH), 134.95 (CH), 134.81 (C), 124.93 (CH), 121.22 (CH), 115.06 (CH), 113.08 (CH), 77.75 (CH), 72.02 (CH), ', 71.94 (CH2), 70.76 (CH2), 68.7i' (CH), 67.78 (CH2), 66.50 (CH2), 55.46 (CH), 49.93 (t~H), 42.47 (CH2), 25.85 (CH2)" 21.75 (CH3), CI MS, m/z calcd. for C24H34~7CI, (fNH'), 469.1993, found 469.19!33.
._ ,.
EXAMPLE 2: Synthesis of 13,14-Dihydrofluprostenol Isopropyl Ester v o o~
o-CF' CFA
O ~
THPO THPO
CFA CFs ~~~e~~~~
THP~ THP
hlPO ~ O
~CF~ CFA
~t ~! fr~,~/~/
CFA
a ~~ ~ ~~~ ~, A~ (3aR 4R 5R ~aS~i-Hey;ahyrdrp~h~rdroxy~4-j(~f3)-~3-trifl~~~nethyrla~hen~L
3-h~ d~ roxy~-1-bu~yrll 2H c..ytclo~(~ran-2-onQ (2S) A mixture of 1.2 g (3.2 mmol) of diol 25 (for synthesis of diol 25, see U.S.
Patent 4,321,275) and 0.05 g of 10% (wt/wt) Pd/C in 20 mL of methanol was hydrogenated at 30 psi for 1.5 hours. After filtration through a short pad of Celite~
concentration afforded 1.2 g of 26 as a colorless oil. 'H NMR (CDC13) 8 7.44 (m, 2 H), 7.12 (m, 2 H), 4.95 (dt, 1 H), 4.15-3.80 (m, 4 H), 2.82 {dd, J = 10.8, 1 H), 2.55 (m, 2 H), 2.3 (m, 1 H), 2.1-1.3 (m, 6 H). , to B' (3aR 4R 5LR3 6aS, -LHe~~h_ydro-5_ltetrah~ drop' rar_. n~2-) I(~r)-4:j~3y-4-(3-triflsaoromethyrl,~hgnoxy,~-3- ( etrahyrdrol~yrran2-ylox)t)i-1-buty~~~y~lo,penta[~lfuran_ 2-one (27) A mixture of 1.2 g (3.2 mmol) of diol 26 and 0.05 g of p-toluenesulfonic acid monohydrate in 100 mL of ~CHzCl2 at 0 °C was treated with dihydropyran (1.1 ml, 12 mmol) and the salution was stirred for 2 h at 0 °C. After pouring into saturated NaHC03, phases were separated and the organic layer was dried over MgS04, filtered, concentrated, and purified by chromatography on silica gel (1/1, hexanes/
EtOAc) to afford 1.1 g of 2T as a clear, colorless oil. 'H NMR (CDCI3) 8 8.04 (dd, J = 7.0, 1.6, 1 H), 7.44 (m, 2 H), 7.12 (m, 1 H), 4.95 (dt, 1 H), 4.8 (m, 1 H), 4.7 (m, 2o 2 H), 4.15-3.80 (m, 4 H), 3.5 (m, 2 H), 2.82 (dd, J = 10.8, 1 H), 2.55 (m, 2 H), 2.3 (m, 1 H), 2.1-1.3 (m, 6 H).
C: (5ZLr(~,~~ ~( R. ~y-11 r -17 1 1 tetranor-16-(3-triflu_Qr~methvlahenoxv)-5-arostenoic acid isonronvl ester 1317 To a solution of 2.1 g (3.9 mmol) of 27 in 100 mL of THF at -78 °C
was added 3.9 mL (5.8 mmol) of a 1.5 M solution of diisobutyaluminum hydride in toluene. The solution was stirred for 2 h, then quenched by the sequential addition of 0.4 mL of isopropanol at -78 °C followed by 0.4 mL of water at 23 °C. Volatiles were removed under reduced pressure and the aqueous solution was extracted with Et20/EtOAc {1/1 ). Organic extracts were dried over MgSO~, filtered, and concentrated to furnish 1.9 g of lactof 28.
To a 250 mL 3-necked round boiltom flask equipped with a mechanical stirrer and a thermometer were added anhydrous DMSO (100 mL) and NaH (80%
dispersion in mineral oil; 0.48 g, 16 mmol). The mixture was heated to 75 °C
(internal) for 30 min, after which it was allowed to cool to room temperature for 1 h.
Phosphonium bromide 29 (3.5 g, 8 mmol) was then added. After stirring for 30 ,o minutes, 1.9 g {3.5 mmol) of l;actol 28 in 50 mL of DMSO was added, and the resulting solution was heated to 50 °C for 2 h and then brought to room temperature for 16 h. The solution was then poured into 100 mL of water and approximately 2 mL of 50% NaOH added. The aqueous phase was extracted with ether (3 X 100 mL), then made acidic (pH = 5.5) by the addition of a 10%
citric ,s acid solution, and extracted with Et2O:hexanes 2:1 (3 X 100 mL). The combined organic extracts were dried over MgS04., filtered, and concentrated to afford 1.9 g of 30 as a colorless oil.
To 1.9 g of carboxylic acid 30 dissolved in 10 mL acetone was added 0.95 g (6.0 mmol) of DBU and 1.0 g x;6.1 mmol) of isopropyl iodide 1.0 g (6.1 mmol) at 23 °C. After 16 h, the solutions was poured into 100 mL of water and extracted with 100 mL of EtOAc. The organic extract was dried over MgS04, filtered, concentrated, and purified by ;silica gel chromatography (3/2, hexanes/EtOAc) to afford 1.9 g of isopropyl ester 31 as a colorless oil. 'H NMR (CDC13) ~ 7.44 {t, 1 IH), 7.12 (d, 1 H), 7.12 (dd, 2 H), 5.5-5.3 (m, 2 H), 4.99 (heptet, 1 H), 4.15-3.80 (m, z5 4 H), 2.82 {dd, J = 10.8, 1 H), 2.55 (rn, 2 H), 2.3 (m, 1 H), 2.1-1.3 (m, 24 H), 1.23 {s, 3 H), 1.20 (s, 3 H).
,. ("r fT ~, .
Dy (5Z)-(9S 11 R 15R)-17.18.1 c~ 20-Tetranor-16=(3~rifluorom t~hyl)-9 11.15-~r_iydrox~r-5-arostenoic a i~soor~~l_ este_r~~.
Ester 31 (1.9 g, 2.8 mmol) was dissolved in 14 mL of a mixture of AcOH/THFIH20 (4I2I1 ) and the solution was heated to 50 °C for 1 h, allowed to s cool to 23 °C, poured into a saturated solution of NaHC03, and extracted with Et20 (2 X 100 mL) and EtOAc (100 rnL). The combined organic extracts were dried over MgSO4, filtered, concentrated, and purified by silica gel chromatography (1/1, hexanesIEtOAc) to furnish 0.5 g of triol 6 as a clear, colorless oil. 'H NMR
(CDC13) 8 7.44 (t, J = 7.8, 1 H), 7.12 (dd, J = 7.8, 2.0, 1 H), 7.12 (ddd, J =
15.6, ,0 7.2, 2.0, 2 H), 5.5-5.3 (m, 2 H), 4.99 (heptet, J = 6.3, 1 H), 4.15-3.80 (m, 4 H), 3.2 (d, 1 H), 2.95 (s, 1 H), 2.82 (dd, J = 10.8, 1 H), 2.75 (d, J = 5,9, 1 H), 2.55 (m, 2 H), 2.3 (m, 1 H), 2.1-1.3 (m, 24 H), 1.23 (s, 3 H), 1.20 (s, 3 H). CMR (CDC13) ~
173.5, 158.7, 132.1, 131.5, 130.0, 129.5, 129.2, 123.3, 120.8, 117.7, 117.6, 11 i .4, 111.4, 78.6, 74.4, 72.4, 69.9, 6 ~'.6, 52.6, .51.7, 42.5, 34.0, 31.5, 29.4, 26.8, 26.6, ,s 24.9, 21.7.
EXAMPLE 3: Synthesis of Cloprostenoi-1-of (7) o a-i i t ~ ~yccN~a~
° ~° ~ /
n.~PO APO niPO n~Pa a a is a ° _.... ~~°~ ~ ~
n~r~ ~~ n~PO ,rPo a a a se A: (5Z. 13EL(9S, 11 R, l5Ry-11.l5;Bis~(tetrahydropvran-2-yloxy~-16-(3-chlorophenox~r~-9-h~ di rox~ -ii 7.18.19,20-tei:ranor-5.13 prosta ienoic acid i~S~~ro~yrl A 1.5 M solution of diisobutylaluminum hydride in toluene (10 mL, 15 mmol) was added dropwise to a solution of 5.8 g (11.4 mmol) of lactone 16 in 55 mL
of THF at -78 °C. After 1 h, 10 ml_ of methanol was added dropwise, and the mixture was stirred for 10 rnin at -78 °C before being warmed to room temperature. The ', ,o mixture was then poured into 100 mL of a 1/1 solution of saturated aqueous potassium sodium tartrate/ethyl acetate and stirred. After separating layers, the aqueous phase was extracted vvith ethyl acetate (2 X 40 mL). Combined organic layers were dried over MgS04, filtered, concentrated, and purified by silica gel chromatography (3/2, ethyl acei:ate/hexane), to afford 4.4 g (76%) of lactol 33, ,s which was used immediately in the next step.
A 1 M solution of potassium t butoxide in THF (50.0 mi) was added dropwise to 12.1 g (27.3 mmol) of phosplnonium salt 29 in 100 mL of THF at 0 °C.
After 30 min, a solution of 4.4 g (8.6 mmol) of lactol 33 in 20 mL of THF was added dropwise, and the mixture was stirred at room temperature overnight. The solution was then poured into 150 mL of a 1/1 mixture of ethyl acetatelsaturated NH4C1.
Layers were separated and the aqueous layer was extracted with ethyl acetate (2 X 100 mL). Combined organic layers were dried over MgSO~, filtered, concentrated, and the residue vvas redissolved in 80 mL of acetone. To this was added 6.5 g (45 mmol) of DBU followed by 7.3 g (43 mmol) of isopropyl iodide.
25 After stirring overnight, the reacaion was poured into 100 mL of a 1/1 mixture of ethyl acetate/saturated NH4C1. Layers were then separated and the aqueous phase was further extracted with ethyl acetate (2 X 100 mL). The combined organic layers were dried over MgS04, fi8tered, concentrated, and purified by silica gel chromatography (40% ethyl acetate in hexane) to afford 2.92 g (53% from so lactone 16) of ester 34.
,?2 8~ ~.SZ. 13 E~ (9S. 11 R. 15 Ry-1 fi- 3-Chlorol~henox)~, -17.1$,19.20-tetranor-9.11.15-trihvdrox) -5.~ 13-orQstadienol (7) ' A solution of 500 mg (0.79 mmol) of 34 in 10 mL of THF was added dropwise to 61 mg (1.60 mmol) of lithium aluminum hydride in 20 mL of THF at s 0 °C. After 40 min, the reaction was poured into 15 mL of saturated NH4C1, and the mixture was then extracted with ethyl acetate ( 3 X 40 mL). Combined organic layers were dried over MgS04 , filtered, and concentrated to afford 500 mg of crude 35.
To a solution of 500 mg of 35 in 20 mL of methanol was added 0.5 mL of 2 ,o H4 HCI. After 1 h, the reaction was quenched with 20 mL of saturated NaHC03 and the mixture was extracted with ethyl acetate (4 X 30 mL). The combined organic layers were dried over MgS04, filtered, aind concentrated. Silica gel chromatography (EtOAc) provided 101 mg (31 % from 34} of 7. '3C NMR (CDC13) 8 159.27 (C), 135.44 (CH), 134.82 (C), 13C).64 (CH), 130.26 (CH), 128.23 (CH), ,s 121.25 (CH), 115.07 (CH), 113..08 (CH}, 77.35 (CH), 72.35 (CH), 71.90 (CH?), ' 70.89 (CH), 62.22 (CHZ), 55.40 (CH), 49.87 (CH), 42.79 (CH2), 31.83 (CH2), 26.77 (CH2), 25.60 (CH2), 25.33 (CH2). CI MS m/z calcd for C22H3205C1, (MH+) 411.1938, found 411.1938.
'~~~~ ~_ EXAMPLE 4: Synthesis oif 13,14-Dilhydrocloprosteno!-1-cal Pivaloate (S) o~
o~ ~ r ero ~ °~ ezo ~ °~ , c.
O
_ gt~ Ph~P'fCH~I~
THPO THPO 1~ ~ Ly ~OOaPr-1 THPO
THPO TH
4d ~qa l~p,~p~ ~ ~"~~./~' t~ . ~ ~ Me, p~ ~ ~ ~ ,~ w ~tr~ tt~ rNPO ~~ a ci a ~ v 4a ~;~
r A~3aR 4R 5R 6aS -4-fl3R~~-4- 3- hlo~phenox~~)-3-h~rdroxa~rl] hexahy dry 0 5 hyrdrox~ -~ 2H-cycloloentaL~~f .~~n-2-one (3~:
A mixture of 2.4 g (5.4 mmol) of 14 and 250 mg of 10% {wt/wt) PdIC in 35 s mL of ethyl acetate was hydrogenated at 40 psi for 1 h. After filtration through a short pad of Celite, the filtrate was evaporated down to 2.3 g (100%) of hydrogenated product 36.
The crude benzoate 36 was dissolved in 25 mL of methanol, and 610 mg (4.4 mmol) of K2C03 was add~sd. After 3.5 h, the mixture was poured into 100 mL
,o of water/ethyl acetate (1/1 ). Layers were separated, and the aqueous phase was further extracted with ethyl acetate (2 X 50 mL). The combined organic layers were dried over MgS04, filtered and concentrated. Silica gel chromatography (EtoAc) provided 1.50 g (82%) of 37 as a white solid, m.p. = 102.0-103.5 °C. 'H
NMR ~ 7.22 (t, J = 8.2 Hz, 1 H), 7.0-6.94 (m, 1 H), 6.91-6.88 (t, J = 2.1 Hz, 1 H), ,s 6.83-6.77 (m, 1 H), 4.97 (dt, J = 3.0, 8.3 Hz, 1 W), 4.12-3.91 {m, 3 H), 3.82 (dd, J =
7.4, 9.0 Hz, 1 H), 2.85 (dd, J == 8.0, 16.5 Hz, 1 H), 2.6-1.4 (m, 11 H).
IB: (3aR. 4R 5R. 6a,~,1-4-f(3R'n-4-(3-Chloral henoxy~-3-(~etr~hy~iroa~~rran 2 y,Loxxybu~~]-hexah~ dry o-5-(tPtrahvdroavran-2-~ I~ox~y-2H-~y~~ nta~'~-jfuran-2-one (38) Dial 37 (3.4 g, 10 mmol) and 2.2 g (26 mmol) of 3,4-dihydro-21-d pyran were dissolved in 80 mL of CH2C12, and 240 mg (1.3 mmol) of p-toluenesulfonic acid monohydrate was added at 0 "C. After 1 h, the reaction was poured into 50 mL
of saturated NaHC03 and the mi;dure was extracted with CH2CI2 (3 X 40 mL). The combined organic layers were dried over MgS04, filtered, concentrated, and the s residue was chromatographed on silica gel (hexane/ethyl acetate, 1/1) to afford 4.5 c,~ (87%) of bis-THP ether 38.
~~i C: ~5Z)-(9S 11 R 15R,-1~-Bisltetrah~~o~~~ rr an-2yloxy~-1~-(3-chloropenoxy~-9-~droxy-17 18,19 20-tetranor-;5prostenoic acid iso~l r~oh~Lester (41,) A 1.5 M solution of diisobutylaluminum hydride in toluene (1.8 mL, 2.7 mmol) was added to the solution 1Ø5 g (2.06 mmol) of 38 in 10 mL of THF at -78 °C.
s After 1 h, 4 mL of methanol was added and the mixture was warmed to 25 °C, then poured into 40 mL of ethyl ac,=tate/saturated aqueous potassium sodium tartrate (1l1). Layers were separated and the aqueous phase was further extracted with ethyl acetate (3 X 30 mL). The combined organic layers were then dried over MgSO4, filtered, concentrated, and the residue was chromatographed on silica gel ,o (ethyl acetate) to afford 740 mg (70%) of lactol 39.
A 1.5 M solution of potassium t butoxide in THF (8.6 mL, 8.6 mmol) was added dropwise to a mixture of 15 mL of THF and 1.92 g (4.33 mmol) of phosphonium salt 29 at 0 °C. After stirring 1 h, a solution of 740 mg (1.45 mmol) of lactol 39 in 5 mL of THF was added dropwise, and the reaction was allowed to ,s warm to 25 °C overnight. The mixture vvas then poured into 100 mL of ethyl acetate/saturated NH4C1 (1/1). Layers were separated, and the aqueous phase 'was further extracted with eth,rl acetate (2 X 70 mL). Combined organic layers were dried over MgS04, filtered, and concentrated to afford 1.6 g of crude acid 40.
Crude acid 40 (1.6 g) was dissolved in 11 mL of acetone and cooled to 0 °C, ilhen 850 mg (5.6 mmol) of De~U was added dropwise to the solution. The resulting mixture was stirred for 15 min at 0 °C and 30 min at 25 °C, after which 850 mg (5.0 mmol) of isopropyl iodide was added. The reaction was stirred overnight, poured into 100 mL of ethyl acetatels<~turated NH4C1 (1l1 ). Layers were separated, and l:he aqueous phase was further extracted with ethyl acetate (2 X 50 mL).
2s Combined organic layers were dried over MgSO~, filtered and concentrated.
The resulting residue was purified by silica gel chromatography (ethyl acetate/hexanes, 3/2) to afford 560 mg (61 % from lactol 39) of isopropyl ester 41.
D' ~5Z)-(9S 11 R. 15R~-16- 3-c;hloronhenoxy.~;17 18 19.20-tetranor-9.11.15-trih~droxy-5-prostenyl pivaloate A solution of 400 mg (0.63 mmol) of 41 in 5 mL of THF was added dropwise to a suspension of 35 mg (0.92 mmol) of lithium aluminum hydride in 5 mL of THF
s at 0 °C. After 2 h, the reaction was poured into 50 mL of a 1/1 mixture of ethyl acetate/saturated NaHC03. Tha layers were then separated, and the aqueous phase was extracted with ethyl acetate (2 X 2 mL). Combined organic layers were dried over MgS04, filtered, and concentrated. The resulting residue purified by silica gel chromatography (ethyl acetate) to afford 350 mg (95%) of dial 42.
,o Pivaloyl chloride (90 mg, 0.75 mmol) was added to a mixture of 350 mg (0.60 mmol) of 42, 60 mg (0.76 mmol) of pyridine, 22 mg (0.18 moral) of 4-(dimethylamino)pyridine, and 7 mL of CH2CIz. After 1.5 h the mixture was poured into 30 mL of saturated NH4C1/ethyl acetate (1/1 ). Layers were then separated and the aqueous phase was extracted with ethyl acetate (2 X 20 mL). The combined ,s organic layers were dried over MgS04, filtered, concentrated, and purified by silica gel chromatography (ethyl acetate/hexane, 3/2) to afford 370 mg (93°/~) of pivaloate 43.
Water (10 drops) and concentrated HCI (3 drops) were added to a solution of 370 mg (0.56 mmol) of 43 inn 5 mL of methanol. After stirring overnight, the zo reaction was quenched by the addition of 20 mL of saturated NaHC03, and the mixture was extracted with ethyl acetate (3 X 20 mL). The combined organic layers were dried over MgS04, filtered, and concentrated. The residue was chromatographed on silica gel (ethyl acetate/hexane, 312), to afford 165 mg (59%) of trio) 8. '3C NMR (CDC13) 8 178.77 (G), 159.27 (C), 134.80 (C), 130.20 (CH), zs 128.62 (CH), 121.19 (CH), 11 4.97 (CH), 112.97 (CH), 78.50 (CH), 74.46 (CH), 72.31 (CHz), 69.86 (CH), 64.16 (CHz), 52.53 (CH), 51.67 (CH), 42.50 (CHz), 31.51 (CHz), 29.40 (CHz), 28.10 (CHz), 27.12 (CH3), 26.77 (CHz), 26.65 (CHz), 25.77 (CHz). CI MS, mlz calcd for Cz7H4,OsCl, (MH+), 497.2670, found 497.2656 The studies detailed in the following Examples 5-9 compared the IOP
lowering activity and side effects of five compounds: A) Cloprostenol, isopropyl ester; B) Fluprostenol, isopropyl ester; C~) 16-Phenoxy-17,18,19,20-tetranor PGF2a, isopropyl ester; D) 17-Phenyl-18,19,20-trinor PGF2a, isopropyl ester; and E) 13,14-s Dihydro-17-phenyl-18,19,20-trir~or PGF2a, isopropyl ester (latanoprost). The structures of these compounds are shown in the following Table 2.
Table 2 COMPOUND NAAAE COMPOUND STRUCTURE
A Cloprostenol, isopropyl Ester HO ,.\ °~
~~ v °
Ho = ° \ /
OH
CI
B Fluprostenol, isopropyl ester O-° ', HO = ° \
OH
C 16-Phenoxy-17,18,19,20-tetranor PGF2a, isopropyl ester O
~o Ho = ° \ /
off D 17-Phenyl-18,19,20-trinor PGF2a, isopropyl ester ~ °
'~ ~ O
Ho OH \
E 13,14-Dihydro-17-phenyl 18,19,20-trinor PGFza, isopropyl ~ °
ester s HO - \
OH
~~t ~u As is apparent in Table 2, the five compounds differ only slightly in structure;
(however, as Examples 5 and s5 will show, such seemingly slight structural differences produce greatly different IOP-lowering effects and levels of hyperemia.
Compounds A-E (Table 2, abovey were tested for hyperemia in the guinea pig. The objective of the guinea pig conjunctiva) hyperemia model is to provide a ,o primary screening indication ov the potential of a prostaglandin for inducing conjunctiva) hyperemia in humans.
Guinea pigs were maintained in their cages during the study, and removed only for scoring and dosing. Eyes were evaluated using a magnifying lens with fluorescent illumination and scores far conjunctiva) hyperemia were recorded for ,5 upper bulbar conjunctiva according to the following criteria:
0 = Narmal appearance of vessels at limbus and on superior recfus muscle +1 - Enlargement of vessels normally visible of limbus and on superior rectus muscle zo f2 = Branch of vessels at limbus, new vessels visible f3 = New vessels visible in open bulbar conjunctiva) areas f4 - Diffuse redness i'n open bulbar conjunctiva) areas Scores of 0 or 1 indicated no hyperemia, and scores of 2-4 indicated hyperemia (a zs score of 4 indicating the most hyperemia). Only integer scores were permitted in order to minimize subjectivity.
Baseline observations were made prior tv unilateral dosing with a 10 NL. ', aliquot of either the prostaglandin test formulation or the control formulation, followed by observations at 1, 2, 3 and 4 hours after dosing. Groups typically so contained four animals, but ranged up to eight animals per group. The results of the study are presented in Taiole 3, below, as percent frequency of each score, and in Figure 1 as percent incidence of hyperemia, defined as the percent of scores of +2 or +3 relative to the total number of observations for each dose.
p * M N CO N
Z N r r M et c0 ~ N O
N ~ M M ~ ~
Z
O m ', r O
U ~ ~ ~ iW ~
.
t7 o co ~ o T ~
r ~ ~ ~ ~
Z N
M M '~t00 N O
M
* I
~ ~ ' N M Q~ N h O
O N (O N ' C
r r O <] r CO tn CO CO
ih ' C
O N h- O ~ ~
* (O t0~ Ln C Z N r ~C OL t- ', M O O O N O ~
V
N t~.O tf) M O
O
.
. r m ~i r O
U
O
Cn r M 00 ~-- N ~
C N
M C~ h t0 O O N d!' M u1 .- N h-M
O * tn t0 Ca (O ~ p ,0 z N
M O O O O O
I~I
s O
N O ~ M O O
W
~ U
r O O ~i' '~f O
t0 t~ U,7 t1y N
V
C
M ~ m C
a0 N m m ~
m ~ N O~ ' N
O
~
G ~ ~
N ' ~ C
_ ~ ~ ~ C.
~. V1 tn m N tD O
;
O Q.. O O p_ ~ O ~ ' t!f .C et p~ ~' ' C~
m a ~. a- m o ~~ ~ N M
" ~ ~ co ~ ' ~
~ . c LL o . . U U_..~r ~r ~Q. ~
p lLC ~
Q a1 ~J~ .. W r~ Zz m G9~a . *
N ~ N N
~iscussion:
Compound C (16-phenoxy-17,18,19,20-tetranor PGF2a, isopropyl ester) produces significant hyperemia at low doses, and at 0.3 and 1.0 Ng doses, all eyes received one or more scores of +3. Compound D (17-phenyl-18,19,20-trinor PGFZa, isopropyl ester) produce's less hyperemia than compound C, but significantly more than compound E (13,14-dihydro-17-phenyl-18,19,20-trinor PGF2a, isopropyl ester), which produces only mild hyperemia. The hyperemia produced by compound A (cloprostenol, isopropyl ester) and compound B ', ,o (fluprostenol, isopropyl ester) appear to be intermediate between that of compound ~ and compound E, but this degree of hyperemia is also mild, and cannot be distinguished from that produced by compound E.
,s EXAIMPLE 6 In the study presented below, compounds A-E (Table 2, above) were tested for IOP-lowering effect in cynornolgus monkey eyes.
The right eyes of the cynomolgus monkeys used in this study were zo previously given laser trabeculoplasty to induce ocular hypertension in the lasered eye. Animals had been trained to sit in restraint chairs and conditioned to accept experimental procedures without chemical restraint. IOP was determined with a pneumatonometer after light corneal anesthesia with dilute proparacaine. The test protocol included a five-dose treatment regimen because of the typical delayed 2s response to prostaglandins. The designated test formulations were administered to tlhe lasered right eyes, and the normal left eyes remained untreated, although IOP
measurements were taken. l3a;seline IOF' values were determined prior to treatment vvith the test formulation, and then IOP was determined from 1 to 7 hours after the first dose, 16 hours after the fourth dose, and 1 to 4 hours after the fifth dose.
o Results are presented in Tables 4 and 5, below, and in Figures 2 and 3, as the rnean percent reduction of IOP from baseline t SEM. Prostaglandin doses are .
micrograms of compound contained in each treatment with 10 IaL of the test formulation. In Table 4, the same amount (0.3 lag) of each of compounds A-E
were compared for IOP reduction. In Table 5, various amounts of compound A (0.3 and 1.0 lag) were compared against various amounts of compound E (0.3, 1.0 and 3.0 s lag) in order to determine the dose responses of the two different compounds.
Table 4: Percent IOP (Reduction in Lasered Gynomofgus Monkeys Percent IOP Reduction Compound Baseline (H ours afterst Dose/Dose#) La IOP (mm ,o (isopropyl ester) Hg) 16/4 2/5 4/5 6/5 A (Cloprostenol)36.9 23.6 t 30.2 t 31.2 t 24.4 t 3.3 4.5 6.8 6.9 B (Fluprostenol)41.6 18.4 t 31.2 t 30.3 t 26.6 t 5.9 3.7 3.8 3.6 C (16-Phenoxy-38.2 30.2 t 25.3 t 23.6 t 28.9 t 4.4 4.5 3.8 3.0 17,18,19,20-,s tetranor PGF2~
D (17-Phenyl-18,40.8 25.6 t 36.0 t 39.8 t 30.3 t 2.6 2.4 3.1 2.8 19,20-trinor PGFz~
E(13,14-Dihydro-39.7 7.612.9 3.612.7 7.512.7 8.013.4 2o i7-phenyl-18,19, ', 20-trinor PGF2~
a f~ ~~
(~ ' ~~: ~J
Table 5:
Gornparison of Percent IOP
Reduction Baseline Percent Compound Dose IOP Reduction IOP (rrlm(Hours after Last DoseIDose#) (N9) 9) 1 614 2/5 4l5 6/5 A' 0.3 36.9 23.6:3.3 24.416.9 30.214.5 31.216.8 s A 1 39.6 34.8 ~: 35.8 ~
4.5 36.7 5.1 1 5.8 38.7 1 5.9 E 0.3 39.7 7.6 t 8.0 t 2.9 3.6 3.4 t 2.7 7.5 t 2.7 E** 1 38.9 23.2 3: 20.2 t 3.6 22.0 4.0 t 4.0 18.8 t 5.2 E 3 30.1 11.6 3: 12.7 1 6.5 17.6 5.0 1 5.8 13.1 1 5.0 4tV~JlVJIE711V1, ISVEJPV~YI F3Slf3f ,o *"13,14-Dihydro-17-phenyl-18,19,20-trinor PGF2a, isopropyl ester Discussion:
Table 4. shows that compounds A, B, C, and D produce similar degrees of IOP reduction with 0.3 Ng doses; however, compound E is essentially inactive at ,s . this dose.
In Table 5, it is apparenii that the 90P reduction with 1 Ng of compound A is greater than that produced by 0.3 Ng of compound A, and the response to either of these doses of compound A is greater than the maximum reduction produced by either dose of compound E. Tlhese obss~rvations indicate that compound A
zo (cloprostenol, isopropyl ester) i both more potent and produces a greater rnaximum response for IOP reduction than compound E (13,14-dihydro-17-phenyl-18,19,20-trinor PGF2~. , EXAi'VI P LE 7 PGF2a analogues are known to contract the iris sphincter of cats and this s assay is a generally accepted ~~eference for activity. For this reason, the pupil diameter of cats may be used to define i:he activity of PGFza analogues and, as demonstrated by Stjernschantz and Resul (Drugs Future, 17:691-704 (1992)), predict the IOP-lowering potency.
,o Compounds of the present invention were therefore screened for pupillary constriction in the cat. Data for compounds 6, 7, and 8 are presented in Table 6, below. The response is quantitated as l~rea ,_5 values (area under the pupil cliameter versus time curve from 1-5 hours), and the equivalent response dose (ED5) is estimated from its doss response relationship.
,s Table 6: Cat Pupil Diameter Response Compound EDs ~I~g) PGF2a Isopropyl Ester 0.02 o Cloprostenol Isopropyl Ester 0.01 0.2 0.02 8 0.06 25 Discussion:
The two standard compounds, PGF2a isopropyl ester and cloprostenol isopropyl ester, produced marked change in cat pupillary diameter, displaying EDS
values of 0.02 and 0.01 Ng, res;pectively. Compound 7 (cloprostenol-1-0l) and compound 8 (13,14-dihydrocloprostenol-1-0l pivaioate), displayed nearly equivalent so potency. 13,14-Dihydrofluprostenol isopropyl ester (compound 6) was approximately one order of magnitude less potent, with an EDS of 0.2 lag.
ft, ~~ ~'h In the study presented below, cornpound 6 (Table 1, above) was tested for IOP-lowering effect in cynomolgus monkey eyes. ', s The right eyes of the cynomolgus monkeys used in this study were previously given laser trabeculoplasty to induce ocular hypertension in the lasered eye. Animals had been trained to sit in restraint ehairs and conditioned to accept experimental procedures without chemical restraint. IOP was determined with a pneumatonometer after light corneal anesthesia with c'ilute proparacaine. The test ,o protocol included a five-dose treatment regimen because of the typical delayed response to prostaglandins. The designated test formulations were administered to t:he lasered right eyes, and the normal left eyes remained untreated, although IOP
measurements were taken. Baseline IOF' values were determined prior to treatment rnrith the test formulation, and then IOP vvas determined from 1 to 7 hours after the ,s first dose, 16 hours after the fourth dose, and 1 to 4 hours after the fifth dose.
The equivalent responsE; dose (El~2o) is estimated from the dose response relationship to be the dose producing a 20% peak reduction in IOP.
Tables 7: Monkey lop Response Compound ED2o (N9) PGF2a Isopropyl Ester 0.4 6 0.3 l7iscussion:
As can be seen in Table 7, above, compound 6, the 13,14-dihydro analogue of fluprostenol was quite potent in the monkey IOP model, producing a 20%
reduction at 0.3 Ng. This was even more potent than the standard compound, 3o IPGF2a isopropyl ester. ', r The following Formulations 1-8 are representative pharmaceutical compositions of the invention for topical ring of intraocular pressure.
use in lowe Each of Formulations 1 through 8 may be formulated in accordance with procedures known to those skilled in the art.
FORMULATION ~
,o Ingredient Amount ~wt/4) Cloprostenol isopropyl ester 0.002 (Table 2, Compound A) Dextran 70 0.1 ,5 Hydroxypropyl methylcellulose 0.3 Sodium Chloride 0.77 Potassium chloride 0.12 Disodium EDTA (Edetate 0.05 disodium) 2o Benzalkonium chloride 0.01 ', HCI andlor NaOH pH 7.2 - 7.5 Purified water q.s. to 100%
~a ~A '~ , ~, _ _ ~.' .
Ingredient Amount (wt°/p) Cloprostenol, t butyl ester 0.01 s Monobasic sodium phosphate 0.05 Dibasic sodium phosphate 0.15 (anhydrous) Sodium chloride 0.75 Disodium EDTA (Edetate disodium) 0.01 ,o Benzalkonium chloride 0.02 Polysorbate 80 0.15 HCI and/or NaOH pH 7.3 - 7.4 ', Purified water q.s. to 100%
Ingredient: Amount {wt%) zo Cloprostenol, methyl eater 0.001 Dextran 70 0.1 Hydroxypropyl methylc~ellulose 0.5 Monobasic sodium phosphate 0.05 Dibasic sodium phosphate 0.15 2s (anhydrous) Sodium chloride 0.75 Disodium EDTA (Edeta.te disadium) 0.05 Benzalkonium chloride 0.01 NaOH and/or HCI pH 7.3 - 7.4 so Purified water q.s. to 100%
wr Ingredient Amount (wt%) Fluprostenol isopropyl ester 0.003 (Table 2, Compound B) ', Monobasic sodium phosphate 0.05 Dibasic sodium phosph<~te 0.15 (anhydrous) ,o Sodium chloride 0.75 Disodium EDTA (Edetate disodiurn) 0.05 Benzalkonium chloride 0.01 HCI and/or NaOH pH 7.3 ~ 7.4 Purified water q.s. to 100%
o ingredient Amount Qwt%j Compound 5 (Table 1 ) 0.002 Dextran 70 0.1 Hydroxypropyl methylcellulose 0.3 Sodium chloride 0.77 z5 Potassium chloride 0.12 Disodium EDTA 0.05 Benzalkonium chloride 0.01 HCI andlor NaOH , pH 7.2 - 7.5 Purified water q.s. to i 00%
,~s' G
E,r ,rr ...
Ingredient Amount (wt%) s Compound 6 (Table 1 ) 0.01 Monobasic sodium pho;>phate 0.05 Dibasic sodium phosphate 0.15 {anhydrous) Sodium chloride 0.75 ,o Disodium EDTA 0.01 Benzalkonium chloride 0.02 ';
Polysorbate 80 0.15 ', HCI and/or NaOH pH 7.3 - 7.4 Purified water q.s. to 100% ', ,5 0 Ingredient Amount (wt%) Compound 7 (Table 1 ) 0.001 Dextran 70 0.1 Hydroxypropyl methylce~llulose 0.5 Monobasic sodium phosphate 0.05 25 Dibasic sodium phosphate 0.15 ', (anhydrous) Sodium chloride 0.75 Disodium EDTA 0.05 Benzalkonium chloride 0.01 so NaOH andlor HCI pH 7.3 - 7.4 Purified water q.s. to 100%
~:
FC?RMUL_ATION :3 Ingredient Amount (wt%) ', s Compound 8 (Table 1 ) 0.003 Monobasic sodium pho:~phate 0.05 Dibasic sodium phosphate 0.15 (anhydrous) Sodium chloride 0.75 ,o Disodium EDTA 0.05 ', Benzalkonium chloride 0.01 HCI and/or NaOH pH 7.3 - 7.4 ', Purified water q.s. to 100%
,s The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential 2o characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.
~~.~'' E.: y3aR.4R. 5R.'6aS~-4-[(E)-(3R)-~3-ChIarQ h~~ enoxy~-3-(tetrahvdrop,~n-2-r~lox~-1-butenyll-hexahydro-~ (tetrahvdrvpyran-2-yrlox),Cap-2H-c)~cloaenta(~lfuran-2-one (16~
To a mixture of 5.1 g (11.5 mmol) of 14 in 200 mL of methanol was added 11.7 g (12 mmol) of K2C03. After 1 h, the mixture was poured into 100 mL of 0.5 P~1 HCI and extracted with ethyl acetate (3 X 100 mL). The combined organic layers were washed successively with water (2 X 100 mL) and saturated NaCI (2 X
100 mL). The organic layer was dried over MgSO4, filtered, and concentrated to afford 4.85 g of crude diol 15, °uvhich was used in the next step without further purification.
,o To a mixture of 4.85 g of crude 15 and 2.4 g (28 mmol) of 3,4-dihydro-2H-pyran in 75 mL of CH2C12 at 0 "C was added 370 mg (1.9 mmol) of p-toluenesulfonic acid monohydrate. After stirring for 45 min, the reaction was poured into 40 mL of saturated NaHCO3, layers were separated, and the aqueous layer was extracted with CH2C12 (2 X 40 mL). The combined organic layers were ,s dried over MgSO~, filtered, and concentrated. The residue was chromatographed an silica gel eluting with 40% ethyl acetate in hexanes, to afford 6.0 g (100%) of 1G
as an oil. ' H NM R (CDC13) 8 (characteri stic peaks only) 7.25-7. i 4 (m, 1 H), 6.95-~i.87 (m, 2 H), 6.83-6.72 (m, 1 H), 5.8-5.4 (m, 4 H), 5.1-4.8 (m, 2 H).
zo _F~~13~-(9S. 11 R~15R_~:11 15_Bis(i.etrahydropyran-2-yrlo_x)~) =16-~~3-chlor~c ~hPnoxv)-2.3.4,5.~.17.18.19.20-nc~nanor-9-trieth~lsila~lox5r-l3~rr~steng~~riethXl~il)~th~r (18) To a suspension of 400 mg (10.5 mmol) of lithium aluminum hydride in 20 rnL of THF at 0 °C was added dropwise a solution of 4.5 g (8.8 mural) of lactone 1~ 6 in 20 mL of THF. After 1 h at 0 °C the mixture was cautiously poured into 100 s rnL of a 1/1 mixture of ice-cold saturated NH4CI/ethyl acetate. The layers were separated, and the aqueous layer was extracted with ethyl acetate (2 X 50 mL).
l'he combined organic layers were dried over MgSO~, filtered, and concentrated to afford 4.5 g (100%) of diol 17 ~Nhich was used in the next step without further purification.
30 ' Triethylsilyl chloride (3.0 g, 20 mmol) was added to a mixture of 4.5 g (8.8 rnmol) of crude 17, 40 mL of DMF, 1.85 g (27.0 mmol) of imidazole, and 310 mg (2.5 mmol) of 4-(dimethylamino)pyridine. After 2 h, the reaction was poured into 1100 mL of a 1/1 mixture of ethyl acetate/saturated NH4C1, layers were separated, s and the aqueous layer was extracted with ethyl acetate (2 X 25 mL). The combined organic layers were washed with water (3 X 25 mL), dried over MgS04, and concentrated. The residue was chromatographed on silica gel eluting with 20% ethyl acetate in hexane to afford 5.2 g (80%) of i8. 'H NMR (CDC13) 8 ' (,characteristic peaks only) 7.22-7.12 (m, 1 H), 6.95-6.88 (m, 2 H), 6.83-6.71 (m, 1 ,o H), 5.8-5.4 (m, 4 H), 5.1-4.8 (m, 2 H), 1.0-0.85 (m, 18 H), 0.7-0.5 (m, 12 H).
c~~l3E]-l9S 11 R 15R)-11 l~Bi r hy~ro~yran-2-vlox~~-16- 3-chloroohenoxv)-a~ 4 5 6.17.18.19.20-nonanor-~-triethyl_silvlox) -~ 13- rp ostP~nal (191 To a mixture of 1.6 g (12.6 mmol)~ of oxalyl chloride and 15 mL of CH2C12 at ,5 -78 °C was added dropwise a solution of 1.54 g (19.7 mmol) of DMSO
in 2 mL of GH2Clz . After 10 min, 4.6 g (fi.2 mmol) of bissilane 18 in 8 mL of CH2C12 was .added dropwise. After 95 min, 3.0 g (30 mmol) of NEt3 was added. The mixture was then warmed to room temperature ;and poured into 70 mL of saturated NH4C1.
The solution was extracted with of CH2GI2 ( 3 X 70 mL) and the combined organic zo Ilayers were dried over MgS04, filtered, <~nd concentrated. The residue was chromatographed on silica gel eluting with 20% ethyl acetate in hexane to afford 2.06 g (53%) of 19 as well as 1.5 g (26%) recovered 18. 'H NMR (CDC13) 8 (characteristic peaks only) 9.78 (t, J = 1.4 Hz, 1 H), 7.22-7.12 (m, 1 H), 6.95-6.88 (m, 2 H), 6.83-6.71 (m, 1 H), fi.8-5.4 (m, 4 H) 5.1-4.8 (m, 2 H), 1.0-0.85 (m, 18 H), 2s 0.7-0.5 (m, 12 H).
H-(,~Z 13E~j9S 11 R 15R)-11-15-Bid(tetrahydrol~s,Lan-2~yrlQxy)-1~3-chloro-I henoxy)-2.3 4.17 18 19 20-he~ptanor-9-triethylsilyloxv-5.13-arostadienoic acid ~nethyrl est r 21 To a solution of 1.35 g (4.24 mmol} of phosphonate 20 and 2.60 g (9.84 s mmol) of 18-crown-6 in 20 mL of THF at -78 °C was added dropwise 6.9 mL (3.45 mmol) of a 0.5 M solution in toluene of potassium hexamethyldisilazane. After stirring for 15 min, a solution of 1.65 g (2.64 mmol) of aldehyde 19 in 20 mL
of THF was added dropwise. One hour later, the mixture was poured into 100 mL of saturated NH4CI/ethyl acetate, 1/1, layers were separated, and the aqueous layer ,o eras extracted with ethyl acetaite (3 X 30 mL). The combined organic layers were dried over MgS04, filtered, concentrated and the residue was chromatographed on silica gel eluting with 20% ethyl acetate in hexane to afford 1.135 g (63%) of 21.
'H NMR (CDC13) S (characteristic peaks only) 7.22-7.11 (m, 1 H), 6.97-6.86 (m, H), 6.85-6.75 (m, 1 H), 6.4-6.2 (m, 1 H), 5.8-5.32 (m, 3 H), 3.66 (s, 3 H).
I: (5Z. l3Ey-(9S 11 R, 1581-1'I .15-Bi,~hv ro~yrran-2-a IoC~yr)~-16-~w3-chloro-phenox~C)-2 3.4 17 18 19 20-heatanor-9-triethylsilyi_ox< -~ 5 13_l~rostadien-1-of X221 To a solution of 850 mg (1.25 mmol) of ester 21 in 10 mL of THF at 0 °C
was added 2.4 mL (3.6 mmol) of a 1.5 M solution in toluene of diisobutylaluminum 2o hydride. After 1 h, the mixture was poured into 20 mL of saturated NHbCI
and was extracted with ethyl acetate (3 X 20 mL). Combined organic layers were dried over MgS04, filtered, and concentrated down to 800 mg (98%) of 22 as an oil. 'H NMR
(CDCI3) 8 (characteristic peaks only) 7.25-7.15 (m, 1 H), 6.97-6.90 (m, 2 H), 6.86-6.75 (m, 1 H), 5.81-5.41 (m, 4 H).
,~!~ l5Z l3El~9S 11 R 15F~-1'~-Bis(tetrahydro~yran-2-yl~i,~ 16-~(~'~-chloro hp enox)C~.-53-ox -a 17 18,19 20-teit~nQr-9-triethylsilyloxy-5 13-pr~~dienoictacid ~~~rol~arl ester l23) To a solution of 415 mg (6.37 mmol) of alcohol 22 in 4 mL of THF at -78 °C
so ~rras added dropwise 0.35 mL (0.87 mol) of a 2.5 M solution in hexane of n-BuLi.
After 15 min, this solution was transferred via syringe to a -78 °C
solution of 195 img (1.08 mmol) of isopropyl bromoacetate in 2 mL of THF. The mixture was kept at -78 °C for 40 min, warmed to room temperature overnight, and then poured into 20 mL of a 1/1 mixture of saturated NH4CI/ethyl acetate. Layers were separated, and the aqueous layer was extracted with ethyl acetate ( 2 X 10 mL). The s combined organic layers were dried over MgSOa, filtered, concentrated, and the c~esidue was chromatographed on silica gel (20% ethyl acetate in hexane) to afford 242 mg (53%) of 23 as an oil. 'H NMR (CDC13) 8 (characteristic peaks only) 7.24-7.15 (m, 1 H), 6.97-6.90 (m, 2 H), 6.86-6.75 (m, 1 H), 5.81-5.41 (m, 4 H), 1.57 (d, J
_. 5.7 Hz, 6 H). ' ,o fC: ~(5ZL13~-1,9S 11 R 15~ 16-(3-ChIQr9~henox,r)-3-oxa-17 18 1 ~ ~0-t r r-~l 11 15-i~rih~rdroy -5 13 ros ~clienoic ~~d isopro~~yr_~~,S~,Q~"~,~, To a solution of 230 mg (0.32 mmol) of silane 23 in 5 mL of THF at room temperature was added 0.33 rroL (0.33 mmol) of a 1 M solution of Bu4NF in THF.
,s After 20 min, the reaction was poured into 4 mL of saturated NH4C1 and was extracted with ethyl acetate (4 X 5 mL). The combined organic layers were dried over MgS04, filtered, concentre~ted, and the residue was chromatographed on silica gel (ethyl acetate/hexane, 1/1 ), to afford 126 mg (65%) of desilylated compound 2.4.
2o To 120 mg of 24 in 5 ml_ of methanol was added 0.4 mL of 2 M HCI. After 1 h, the mixture was added to :3 mL of saturated NaHC03, and the resulting mixture was extracted with ethyl acetate (3 X 8 mL). Combined organic layers ' were dried over MgS04, filtered, concentrated. The resulting residue was then chromatographed on silica gel eluting with ethyl acetate to afford 54 mg (56%) of 5.
2s '3C NMR (CDC13) & 169.92 (C), 159.26 (C), 135,13 (CH), 134.95 (CH), 134.81 (C), 124.93 (CH), 121.22 (CH), 115.06 (CH), 113.08 (CH), 77.75 (CH), 72.02 (CH), ', 71.94 (CH2), 70.76 (CH2), 68.7i' (CH), 67.78 (CH2), 66.50 (CH2), 55.46 (CH), 49.93 (t~H), 42.47 (CH2), 25.85 (CH2)" 21.75 (CH3), CI MS, m/z calcd. for C24H34~7CI, (fNH'), 469.1993, found 469.19!33.
._ ,.
EXAMPLE 2: Synthesis of 13,14-Dihydrofluprostenol Isopropyl Ester v o o~
o-CF' CFA
O ~
THPO THPO
CFA CFs ~~~e~~~~
THP~ THP
hlPO ~ O
~CF~ CFA
~t ~! fr~,~/~/
CFA
a ~~ ~ ~~~ ~, A~ (3aR 4R 5R ~aS~i-Hey;ahyrdrp~h~rdroxy~4-j(~f3)-~3-trifl~~~nethyrla~hen~L
3-h~ d~ roxy~-1-bu~yrll 2H c..ytclo~(~ran-2-onQ (2S) A mixture of 1.2 g (3.2 mmol) of diol 25 (for synthesis of diol 25, see U.S.
Patent 4,321,275) and 0.05 g of 10% (wt/wt) Pd/C in 20 mL of methanol was hydrogenated at 30 psi for 1.5 hours. After filtration through a short pad of Celite~
concentration afforded 1.2 g of 26 as a colorless oil. 'H NMR (CDC13) 8 7.44 (m, 2 H), 7.12 (m, 2 H), 4.95 (dt, 1 H), 4.15-3.80 (m, 4 H), 2.82 {dd, J = 10.8, 1 H), 2.55 (m, 2 H), 2.3 (m, 1 H), 2.1-1.3 (m, 6 H). , to B' (3aR 4R 5LR3 6aS, -LHe~~h_ydro-5_ltetrah~ drop' rar_. n~2-) I(~r)-4:j~3y-4-(3-triflsaoromethyrl,~hgnoxy,~-3- ( etrahyrdrol~yrran2-ylox)t)i-1-buty~~~y~lo,penta[~lfuran_ 2-one (27) A mixture of 1.2 g (3.2 mmol) of diol 26 and 0.05 g of p-toluenesulfonic acid monohydrate in 100 mL of ~CHzCl2 at 0 °C was treated with dihydropyran (1.1 ml, 12 mmol) and the salution was stirred for 2 h at 0 °C. After pouring into saturated NaHC03, phases were separated and the organic layer was dried over MgS04, filtered, concentrated, and purified by chromatography on silica gel (1/1, hexanes/
EtOAc) to afford 1.1 g of 2T as a clear, colorless oil. 'H NMR (CDCI3) 8 8.04 (dd, J = 7.0, 1.6, 1 H), 7.44 (m, 2 H), 7.12 (m, 1 H), 4.95 (dt, 1 H), 4.8 (m, 1 H), 4.7 (m, 2o 2 H), 4.15-3.80 (m, 4 H), 3.5 (m, 2 H), 2.82 (dd, J = 10.8, 1 H), 2.55 (m, 2 H), 2.3 (m, 1 H), 2.1-1.3 (m, 6 H).
C: (5ZLr(~,~~ ~( R. ~y-11 r -17 1 1 tetranor-16-(3-triflu_Qr~methvlahenoxv)-5-arostenoic acid isonronvl ester 1317 To a solution of 2.1 g (3.9 mmol) of 27 in 100 mL of THF at -78 °C
was added 3.9 mL (5.8 mmol) of a 1.5 M solution of diisobutyaluminum hydride in toluene. The solution was stirred for 2 h, then quenched by the sequential addition of 0.4 mL of isopropanol at -78 °C followed by 0.4 mL of water at 23 °C. Volatiles were removed under reduced pressure and the aqueous solution was extracted with Et20/EtOAc {1/1 ). Organic extracts were dried over MgSO~, filtered, and concentrated to furnish 1.9 g of lactof 28.
To a 250 mL 3-necked round boiltom flask equipped with a mechanical stirrer and a thermometer were added anhydrous DMSO (100 mL) and NaH (80%
dispersion in mineral oil; 0.48 g, 16 mmol). The mixture was heated to 75 °C
(internal) for 30 min, after which it was allowed to cool to room temperature for 1 h.
Phosphonium bromide 29 (3.5 g, 8 mmol) was then added. After stirring for 30 ,o minutes, 1.9 g {3.5 mmol) of l;actol 28 in 50 mL of DMSO was added, and the resulting solution was heated to 50 °C for 2 h and then brought to room temperature for 16 h. The solution was then poured into 100 mL of water and approximately 2 mL of 50% NaOH added. The aqueous phase was extracted with ether (3 X 100 mL), then made acidic (pH = 5.5) by the addition of a 10%
citric ,s acid solution, and extracted with Et2O:hexanes 2:1 (3 X 100 mL). The combined organic extracts were dried over MgS04., filtered, and concentrated to afford 1.9 g of 30 as a colorless oil.
To 1.9 g of carboxylic acid 30 dissolved in 10 mL acetone was added 0.95 g (6.0 mmol) of DBU and 1.0 g x;6.1 mmol) of isopropyl iodide 1.0 g (6.1 mmol) at 23 °C. After 16 h, the solutions was poured into 100 mL of water and extracted with 100 mL of EtOAc. The organic extract was dried over MgS04, filtered, concentrated, and purified by ;silica gel chromatography (3/2, hexanes/EtOAc) to afford 1.9 g of isopropyl ester 31 as a colorless oil. 'H NMR (CDC13) ~ 7.44 {t, 1 IH), 7.12 (d, 1 H), 7.12 (dd, 2 H), 5.5-5.3 (m, 2 H), 4.99 (heptet, 1 H), 4.15-3.80 (m, z5 4 H), 2.82 {dd, J = 10.8, 1 H), 2.55 (rn, 2 H), 2.3 (m, 1 H), 2.1-1.3 (m, 24 H), 1.23 {s, 3 H), 1.20 (s, 3 H).
,. ("r fT ~, .
Dy (5Z)-(9S 11 R 15R)-17.18.1 c~ 20-Tetranor-16=(3~rifluorom t~hyl)-9 11.15-~r_iydrox~r-5-arostenoic a i~soor~~l_ este_r~~.
Ester 31 (1.9 g, 2.8 mmol) was dissolved in 14 mL of a mixture of AcOH/THFIH20 (4I2I1 ) and the solution was heated to 50 °C for 1 h, allowed to s cool to 23 °C, poured into a saturated solution of NaHC03, and extracted with Et20 (2 X 100 mL) and EtOAc (100 rnL). The combined organic extracts were dried over MgSO4, filtered, concentrated, and purified by silica gel chromatography (1/1, hexanesIEtOAc) to furnish 0.5 g of triol 6 as a clear, colorless oil. 'H NMR
(CDC13) 8 7.44 (t, J = 7.8, 1 H), 7.12 (dd, J = 7.8, 2.0, 1 H), 7.12 (ddd, J =
15.6, ,0 7.2, 2.0, 2 H), 5.5-5.3 (m, 2 H), 4.99 (heptet, J = 6.3, 1 H), 4.15-3.80 (m, 4 H), 3.2 (d, 1 H), 2.95 (s, 1 H), 2.82 (dd, J = 10.8, 1 H), 2.75 (d, J = 5,9, 1 H), 2.55 (m, 2 H), 2.3 (m, 1 H), 2.1-1.3 (m, 24 H), 1.23 (s, 3 H), 1.20 (s, 3 H). CMR (CDC13) ~
173.5, 158.7, 132.1, 131.5, 130.0, 129.5, 129.2, 123.3, 120.8, 117.7, 117.6, 11 i .4, 111.4, 78.6, 74.4, 72.4, 69.9, 6 ~'.6, 52.6, .51.7, 42.5, 34.0, 31.5, 29.4, 26.8, 26.6, ,s 24.9, 21.7.
EXAMPLE 3: Synthesis of Cloprostenoi-1-of (7) o a-i i t ~ ~yccN~a~
° ~° ~ /
n.~PO APO niPO n~Pa a a is a ° _.... ~~°~ ~ ~
n~r~ ~~ n~PO ,rPo a a a se A: (5Z. 13EL(9S, 11 R, l5Ry-11.l5;Bis~(tetrahydropvran-2-yloxy~-16-(3-chlorophenox~r~-9-h~ di rox~ -ii 7.18.19,20-tei:ranor-5.13 prosta ienoic acid i~S~~ro~yrl A 1.5 M solution of diisobutylaluminum hydride in toluene (10 mL, 15 mmol) was added dropwise to a solution of 5.8 g (11.4 mmol) of lactone 16 in 55 mL
of THF at -78 °C. After 1 h, 10 ml_ of methanol was added dropwise, and the mixture was stirred for 10 rnin at -78 °C before being warmed to room temperature. The ', ,o mixture was then poured into 100 mL of a 1/1 solution of saturated aqueous potassium sodium tartrate/ethyl acetate and stirred. After separating layers, the aqueous phase was extracted vvith ethyl acetate (2 X 40 mL). Combined organic layers were dried over MgS04, filtered, concentrated, and purified by silica gel chromatography (3/2, ethyl acei:ate/hexane), to afford 4.4 g (76%) of lactol 33, ,s which was used immediately in the next step.
A 1 M solution of potassium t butoxide in THF (50.0 mi) was added dropwise to 12.1 g (27.3 mmol) of phosplnonium salt 29 in 100 mL of THF at 0 °C.
After 30 min, a solution of 4.4 g (8.6 mmol) of lactol 33 in 20 mL of THF was added dropwise, and the mixture was stirred at room temperature overnight. The solution was then poured into 150 mL of a 1/1 mixture of ethyl acetatelsaturated NH4C1.
Layers were separated and the aqueous layer was extracted with ethyl acetate (2 X 100 mL). Combined organic layers were dried over MgSO~, filtered, concentrated, and the residue vvas redissolved in 80 mL of acetone. To this was added 6.5 g (45 mmol) of DBU followed by 7.3 g (43 mmol) of isopropyl iodide.
25 After stirring overnight, the reacaion was poured into 100 mL of a 1/1 mixture of ethyl acetate/saturated NH4C1. Layers were then separated and the aqueous phase was further extracted with ethyl acetate (2 X 100 mL). The combined organic layers were dried over MgS04, fi8tered, concentrated, and purified by silica gel chromatography (40% ethyl acetate in hexane) to afford 2.92 g (53% from so lactone 16) of ester 34.
,?2 8~ ~.SZ. 13 E~ (9S. 11 R. 15 Ry-1 fi- 3-Chlorol~henox)~, -17.1$,19.20-tetranor-9.11.15-trihvdrox) -5.~ 13-orQstadienol (7) ' A solution of 500 mg (0.79 mmol) of 34 in 10 mL of THF was added dropwise to 61 mg (1.60 mmol) of lithium aluminum hydride in 20 mL of THF at s 0 °C. After 40 min, the reaction was poured into 15 mL of saturated NH4C1, and the mixture was then extracted with ethyl acetate ( 3 X 40 mL). Combined organic layers were dried over MgS04 , filtered, and concentrated to afford 500 mg of crude 35.
To a solution of 500 mg of 35 in 20 mL of methanol was added 0.5 mL of 2 ,o H4 HCI. After 1 h, the reaction was quenched with 20 mL of saturated NaHC03 and the mixture was extracted with ethyl acetate (4 X 30 mL). The combined organic layers were dried over MgS04, filtered, aind concentrated. Silica gel chromatography (EtOAc) provided 101 mg (31 % from 34} of 7. '3C NMR (CDC13) 8 159.27 (C), 135.44 (CH), 134.82 (C), 13C).64 (CH), 130.26 (CH), 128.23 (CH), ,s 121.25 (CH), 115.07 (CH), 113..08 (CH}, 77.35 (CH), 72.35 (CH), 71.90 (CH?), ' 70.89 (CH), 62.22 (CHZ), 55.40 (CH), 49.87 (CH), 42.79 (CH2), 31.83 (CH2), 26.77 (CH2), 25.60 (CH2), 25.33 (CH2). CI MS m/z calcd for C22H3205C1, (MH+) 411.1938, found 411.1938.
'~~~~ ~_ EXAMPLE 4: Synthesis oif 13,14-Dilhydrocloprosteno!-1-cal Pivaloate (S) o~
o~ ~ r ero ~ °~ ezo ~ °~ , c.
O
_ gt~ Ph~P'fCH~I~
THPO THPO 1~ ~ Ly ~OOaPr-1 THPO
THPO TH
4d ~qa l~p,~p~ ~ ~"~~./~' t~ . ~ ~ Me, p~ ~ ~ ~ ,~ w ~tr~ tt~ rNPO ~~ a ci a ~ v 4a ~;~
r A~3aR 4R 5R 6aS -4-fl3R~~-4- 3- hlo~phenox~~)-3-h~rdroxa~rl] hexahy dry 0 5 hyrdrox~ -~ 2H-cycloloentaL~~f .~~n-2-one (3~:
A mixture of 2.4 g (5.4 mmol) of 14 and 250 mg of 10% {wt/wt) PdIC in 35 s mL of ethyl acetate was hydrogenated at 40 psi for 1 h. After filtration through a short pad of Celite, the filtrate was evaporated down to 2.3 g (100%) of hydrogenated product 36.
The crude benzoate 36 was dissolved in 25 mL of methanol, and 610 mg (4.4 mmol) of K2C03 was add~sd. After 3.5 h, the mixture was poured into 100 mL
,o of water/ethyl acetate (1/1 ). Layers were separated, and the aqueous phase was further extracted with ethyl acetate (2 X 50 mL). The combined organic layers were dried over MgS04, filtered and concentrated. Silica gel chromatography (EtoAc) provided 1.50 g (82%) of 37 as a white solid, m.p. = 102.0-103.5 °C. 'H
NMR ~ 7.22 (t, J = 8.2 Hz, 1 H), 7.0-6.94 (m, 1 H), 6.91-6.88 (t, J = 2.1 Hz, 1 H), ,s 6.83-6.77 (m, 1 H), 4.97 (dt, J = 3.0, 8.3 Hz, 1 W), 4.12-3.91 {m, 3 H), 3.82 (dd, J =
7.4, 9.0 Hz, 1 H), 2.85 (dd, J == 8.0, 16.5 Hz, 1 H), 2.6-1.4 (m, 11 H).
IB: (3aR. 4R 5R. 6a,~,1-4-f(3R'n-4-(3-Chloral henoxy~-3-(~etr~hy~iroa~~rran 2 y,Loxxybu~~]-hexah~ dry o-5-(tPtrahvdroavran-2-~ I~ox~y-2H-~y~~ nta~'~-jfuran-2-one (38) Dial 37 (3.4 g, 10 mmol) and 2.2 g (26 mmol) of 3,4-dihydro-21-d pyran were dissolved in 80 mL of CH2C12, and 240 mg (1.3 mmol) of p-toluenesulfonic acid monohydrate was added at 0 "C. After 1 h, the reaction was poured into 50 mL
of saturated NaHC03 and the mi;dure was extracted with CH2CI2 (3 X 40 mL). The combined organic layers were dried over MgS04, filtered, concentrated, and the s residue was chromatographed on silica gel (hexane/ethyl acetate, 1/1) to afford 4.5 c,~ (87%) of bis-THP ether 38.
~~i C: ~5Z)-(9S 11 R 15R,-1~-Bisltetrah~~o~~~ rr an-2yloxy~-1~-(3-chloropenoxy~-9-~droxy-17 18,19 20-tetranor-;5prostenoic acid iso~l r~oh~Lester (41,) A 1.5 M solution of diisobutylaluminum hydride in toluene (1.8 mL, 2.7 mmol) was added to the solution 1Ø5 g (2.06 mmol) of 38 in 10 mL of THF at -78 °C.
s After 1 h, 4 mL of methanol was added and the mixture was warmed to 25 °C, then poured into 40 mL of ethyl ac,=tate/saturated aqueous potassium sodium tartrate (1l1). Layers were separated and the aqueous phase was further extracted with ethyl acetate (3 X 30 mL). The combined organic layers were then dried over MgSO4, filtered, concentrated, and the residue was chromatographed on silica gel ,o (ethyl acetate) to afford 740 mg (70%) of lactol 39.
A 1.5 M solution of potassium t butoxide in THF (8.6 mL, 8.6 mmol) was added dropwise to a mixture of 15 mL of THF and 1.92 g (4.33 mmol) of phosphonium salt 29 at 0 °C. After stirring 1 h, a solution of 740 mg (1.45 mmol) of lactol 39 in 5 mL of THF was added dropwise, and the reaction was allowed to ,s warm to 25 °C overnight. The mixture vvas then poured into 100 mL of ethyl acetate/saturated NH4C1 (1/1). Layers were separated, and the aqueous phase 'was further extracted with eth,rl acetate (2 X 70 mL). Combined organic layers were dried over MgS04, filtered, and concentrated to afford 1.6 g of crude acid 40.
Crude acid 40 (1.6 g) was dissolved in 11 mL of acetone and cooled to 0 °C, ilhen 850 mg (5.6 mmol) of De~U was added dropwise to the solution. The resulting mixture was stirred for 15 min at 0 °C and 30 min at 25 °C, after which 850 mg (5.0 mmol) of isopropyl iodide was added. The reaction was stirred overnight, poured into 100 mL of ethyl acetatels<~turated NH4C1 (1l1 ). Layers were separated, and l:he aqueous phase was further extracted with ethyl acetate (2 X 50 mL).
2s Combined organic layers were dried over MgSO~, filtered and concentrated.
The resulting residue was purified by silica gel chromatography (ethyl acetate/hexanes, 3/2) to afford 560 mg (61 % from lactol 39) of isopropyl ester 41.
D' ~5Z)-(9S 11 R. 15R~-16- 3-c;hloronhenoxy.~;17 18 19.20-tetranor-9.11.15-trih~droxy-5-prostenyl pivaloate A solution of 400 mg (0.63 mmol) of 41 in 5 mL of THF was added dropwise to a suspension of 35 mg (0.92 mmol) of lithium aluminum hydride in 5 mL of THF
s at 0 °C. After 2 h, the reaction was poured into 50 mL of a 1/1 mixture of ethyl acetate/saturated NaHC03. Tha layers were then separated, and the aqueous phase was extracted with ethyl acetate (2 X 2 mL). Combined organic layers were dried over MgS04, filtered, and concentrated. The resulting residue purified by silica gel chromatography (ethyl acetate) to afford 350 mg (95%) of dial 42.
,o Pivaloyl chloride (90 mg, 0.75 mmol) was added to a mixture of 350 mg (0.60 mmol) of 42, 60 mg (0.76 mmol) of pyridine, 22 mg (0.18 moral) of 4-(dimethylamino)pyridine, and 7 mL of CH2CIz. After 1.5 h the mixture was poured into 30 mL of saturated NH4C1/ethyl acetate (1/1 ). Layers were then separated and the aqueous phase was extracted with ethyl acetate (2 X 20 mL). The combined ,s organic layers were dried over MgS04, filtered, concentrated, and purified by silica gel chromatography (ethyl acetate/hexane, 3/2) to afford 370 mg (93°/~) of pivaloate 43.
Water (10 drops) and concentrated HCI (3 drops) were added to a solution of 370 mg (0.56 mmol) of 43 inn 5 mL of methanol. After stirring overnight, the zo reaction was quenched by the addition of 20 mL of saturated NaHC03, and the mixture was extracted with ethyl acetate (3 X 20 mL). The combined organic layers were dried over MgS04, filtered, and concentrated. The residue was chromatographed on silica gel (ethyl acetate/hexane, 312), to afford 165 mg (59%) of trio) 8. '3C NMR (CDC13) 8 178.77 (G), 159.27 (C), 134.80 (C), 130.20 (CH), zs 128.62 (CH), 121.19 (CH), 11 4.97 (CH), 112.97 (CH), 78.50 (CH), 74.46 (CH), 72.31 (CHz), 69.86 (CH), 64.16 (CHz), 52.53 (CH), 51.67 (CH), 42.50 (CHz), 31.51 (CHz), 29.40 (CHz), 28.10 (CHz), 27.12 (CH3), 26.77 (CHz), 26.65 (CHz), 25.77 (CHz). CI MS, mlz calcd for Cz7H4,OsCl, (MH+), 497.2670, found 497.2656 The studies detailed in the following Examples 5-9 compared the IOP
lowering activity and side effects of five compounds: A) Cloprostenol, isopropyl ester; B) Fluprostenol, isopropyl ester; C~) 16-Phenoxy-17,18,19,20-tetranor PGF2a, isopropyl ester; D) 17-Phenyl-18,19,20-trinor PGF2a, isopropyl ester; and E) 13,14-s Dihydro-17-phenyl-18,19,20-trir~or PGF2a, isopropyl ester (latanoprost). The structures of these compounds are shown in the following Table 2.
Table 2 COMPOUND NAAAE COMPOUND STRUCTURE
A Cloprostenol, isopropyl Ester HO ,.\ °~
~~ v °
Ho = ° \ /
OH
CI
B Fluprostenol, isopropyl ester O-° ', HO = ° \
OH
C 16-Phenoxy-17,18,19,20-tetranor PGF2a, isopropyl ester O
~o Ho = ° \ /
off D 17-Phenyl-18,19,20-trinor PGF2a, isopropyl ester ~ °
'~ ~ O
Ho OH \
E 13,14-Dihydro-17-phenyl 18,19,20-trinor PGFza, isopropyl ~ °
ester s HO - \
OH
~~t ~u As is apparent in Table 2, the five compounds differ only slightly in structure;
(however, as Examples 5 and s5 will show, such seemingly slight structural differences produce greatly different IOP-lowering effects and levels of hyperemia.
Compounds A-E (Table 2, abovey were tested for hyperemia in the guinea pig. The objective of the guinea pig conjunctiva) hyperemia model is to provide a ,o primary screening indication ov the potential of a prostaglandin for inducing conjunctiva) hyperemia in humans.
Guinea pigs were maintained in their cages during the study, and removed only for scoring and dosing. Eyes were evaluated using a magnifying lens with fluorescent illumination and scores far conjunctiva) hyperemia were recorded for ,5 upper bulbar conjunctiva according to the following criteria:
0 = Narmal appearance of vessels at limbus and on superior recfus muscle +1 - Enlargement of vessels normally visible of limbus and on superior rectus muscle zo f2 = Branch of vessels at limbus, new vessels visible f3 = New vessels visible in open bulbar conjunctiva) areas f4 - Diffuse redness i'n open bulbar conjunctiva) areas Scores of 0 or 1 indicated no hyperemia, and scores of 2-4 indicated hyperemia (a zs score of 4 indicating the most hyperemia). Only integer scores were permitted in order to minimize subjectivity.
Baseline observations were made prior tv unilateral dosing with a 10 NL. ', aliquot of either the prostaglandin test formulation or the control formulation, followed by observations at 1, 2, 3 and 4 hours after dosing. Groups typically so contained four animals, but ranged up to eight animals per group. The results of the study are presented in Taiole 3, below, as percent frequency of each score, and in Figure 1 as percent incidence of hyperemia, defined as the percent of scores of +2 or +3 relative to the total number of observations for each dose.
p * M N CO N
Z N r r M et c0 ~ N O
N ~ M M ~ ~
Z
O m ', r O
U ~ ~ ~ iW ~
.
t7 o co ~ o T ~
r ~ ~ ~ ~
Z N
M M '~t00 N O
M
* I
~ ~ ' N M Q~ N h O
O N (O N ' C
r r O <] r CO tn CO CO
ih ' C
O N h- O ~ ~
* (O t0~ Ln C Z N r ~C OL t- ', M O O O N O ~
V
N t~.O tf) M O
O
.
. r m ~i r O
U
O
Cn r M 00 ~-- N ~
C N
M C~ h t0 O O N d!' M u1 .- N h-M
O * tn t0 Ca (O ~ p ,0 z N
M O O O O O
I~I
s O
N O ~ M O O
W
~ U
r O O ~i' '~f O
t0 t~ U,7 t1y N
V
C
M ~ m C
a0 N m m ~
m ~ N O~ ' N
O
~
G ~ ~
N ' ~ C
_ ~ ~ ~ C.
~. V1 tn m N tD O
;
O Q.. O O p_ ~ O ~ ' t!f .C et p~ ~' ' C~
m a ~. a- m o ~~ ~ N M
" ~ ~ co ~ ' ~
~ . c LL o . . U U_..~r ~r ~Q. ~
p lLC ~
Q a1 ~J~ .. W r~ Zz m G9~a . *
N ~ N N
~iscussion:
Compound C (16-phenoxy-17,18,19,20-tetranor PGF2a, isopropyl ester) produces significant hyperemia at low doses, and at 0.3 and 1.0 Ng doses, all eyes received one or more scores of +3. Compound D (17-phenyl-18,19,20-trinor PGFZa, isopropyl ester) produce's less hyperemia than compound C, but significantly more than compound E (13,14-dihydro-17-phenyl-18,19,20-trinor PGF2a, isopropyl ester), which produces only mild hyperemia. The hyperemia produced by compound A (cloprostenol, isopropyl ester) and compound B ', ,o (fluprostenol, isopropyl ester) appear to be intermediate between that of compound ~ and compound E, but this degree of hyperemia is also mild, and cannot be distinguished from that produced by compound E.
,s EXAIMPLE 6 In the study presented below, compounds A-E (Table 2, above) were tested for IOP-lowering effect in cynornolgus monkey eyes.
The right eyes of the cynomolgus monkeys used in this study were zo previously given laser trabeculoplasty to induce ocular hypertension in the lasered eye. Animals had been trained to sit in restraint chairs and conditioned to accept experimental procedures without chemical restraint. IOP was determined with a pneumatonometer after light corneal anesthesia with dilute proparacaine. The test protocol included a five-dose treatment regimen because of the typical delayed 2s response to prostaglandins. The designated test formulations were administered to tlhe lasered right eyes, and the normal left eyes remained untreated, although IOP
measurements were taken. l3a;seline IOF' values were determined prior to treatment vvith the test formulation, and then IOP was determined from 1 to 7 hours after the first dose, 16 hours after the fourth dose, and 1 to 4 hours after the fifth dose.
o Results are presented in Tables 4 and 5, below, and in Figures 2 and 3, as the rnean percent reduction of IOP from baseline t SEM. Prostaglandin doses are .
micrograms of compound contained in each treatment with 10 IaL of the test formulation. In Table 4, the same amount (0.3 lag) of each of compounds A-E
were compared for IOP reduction. In Table 5, various amounts of compound A (0.3 and 1.0 lag) were compared against various amounts of compound E (0.3, 1.0 and 3.0 s lag) in order to determine the dose responses of the two different compounds.
Table 4: Percent IOP (Reduction in Lasered Gynomofgus Monkeys Percent IOP Reduction Compound Baseline (H ours afterst Dose/Dose#) La IOP (mm ,o (isopropyl ester) Hg) 16/4 2/5 4/5 6/5 A (Cloprostenol)36.9 23.6 t 30.2 t 31.2 t 24.4 t 3.3 4.5 6.8 6.9 B (Fluprostenol)41.6 18.4 t 31.2 t 30.3 t 26.6 t 5.9 3.7 3.8 3.6 C (16-Phenoxy-38.2 30.2 t 25.3 t 23.6 t 28.9 t 4.4 4.5 3.8 3.0 17,18,19,20-,s tetranor PGF2~
D (17-Phenyl-18,40.8 25.6 t 36.0 t 39.8 t 30.3 t 2.6 2.4 3.1 2.8 19,20-trinor PGFz~
E(13,14-Dihydro-39.7 7.612.9 3.612.7 7.512.7 8.013.4 2o i7-phenyl-18,19, ', 20-trinor PGF2~
a f~ ~~
(~ ' ~~: ~J
Table 5:
Gornparison of Percent IOP
Reduction Baseline Percent Compound Dose IOP Reduction IOP (rrlm(Hours after Last DoseIDose#) (N9) 9) 1 614 2/5 4l5 6/5 A' 0.3 36.9 23.6:3.3 24.416.9 30.214.5 31.216.8 s A 1 39.6 34.8 ~: 35.8 ~
4.5 36.7 5.1 1 5.8 38.7 1 5.9 E 0.3 39.7 7.6 t 8.0 t 2.9 3.6 3.4 t 2.7 7.5 t 2.7 E** 1 38.9 23.2 3: 20.2 t 3.6 22.0 4.0 t 4.0 18.8 t 5.2 E 3 30.1 11.6 3: 12.7 1 6.5 17.6 5.0 1 5.8 13.1 1 5.0 4tV~JlVJIE711V1, ISVEJPV~YI F3Slf3f ,o *"13,14-Dihydro-17-phenyl-18,19,20-trinor PGF2a, isopropyl ester Discussion:
Table 4. shows that compounds A, B, C, and D produce similar degrees of IOP reduction with 0.3 Ng doses; however, compound E is essentially inactive at ,s . this dose.
In Table 5, it is apparenii that the 90P reduction with 1 Ng of compound A is greater than that produced by 0.3 Ng of compound A, and the response to either of these doses of compound A is greater than the maximum reduction produced by either dose of compound E. Tlhese obss~rvations indicate that compound A
zo (cloprostenol, isopropyl ester) i both more potent and produces a greater rnaximum response for IOP reduction than compound E (13,14-dihydro-17-phenyl-18,19,20-trinor PGF2~. , EXAi'VI P LE 7 PGF2a analogues are known to contract the iris sphincter of cats and this s assay is a generally accepted ~~eference for activity. For this reason, the pupil diameter of cats may be used to define i:he activity of PGFza analogues and, as demonstrated by Stjernschantz and Resul (Drugs Future, 17:691-704 (1992)), predict the IOP-lowering potency.
,o Compounds of the present invention were therefore screened for pupillary constriction in the cat. Data for compounds 6, 7, and 8 are presented in Table 6, below. The response is quantitated as l~rea ,_5 values (area under the pupil cliameter versus time curve from 1-5 hours), and the equivalent response dose (ED5) is estimated from its doss response relationship.
,s Table 6: Cat Pupil Diameter Response Compound EDs ~I~g) PGF2a Isopropyl Ester 0.02 o Cloprostenol Isopropyl Ester 0.01 0.2 0.02 8 0.06 25 Discussion:
The two standard compounds, PGF2a isopropyl ester and cloprostenol isopropyl ester, produced marked change in cat pupillary diameter, displaying EDS
values of 0.02 and 0.01 Ng, res;pectively. Compound 7 (cloprostenol-1-0l) and compound 8 (13,14-dihydrocloprostenol-1-0l pivaioate), displayed nearly equivalent so potency. 13,14-Dihydrofluprostenol isopropyl ester (compound 6) was approximately one order of magnitude less potent, with an EDS of 0.2 lag.
ft, ~~ ~'h In the study presented below, cornpound 6 (Table 1, above) was tested for IOP-lowering effect in cynomolgus monkey eyes. ', s The right eyes of the cynomolgus monkeys used in this study were previously given laser trabeculoplasty to induce ocular hypertension in the lasered eye. Animals had been trained to sit in restraint ehairs and conditioned to accept experimental procedures without chemical restraint. IOP was determined with a pneumatonometer after light corneal anesthesia with c'ilute proparacaine. The test ,o protocol included a five-dose treatment regimen because of the typical delayed response to prostaglandins. The designated test formulations were administered to t:he lasered right eyes, and the normal left eyes remained untreated, although IOP
measurements were taken. Baseline IOF' values were determined prior to treatment rnrith the test formulation, and then IOP vvas determined from 1 to 7 hours after the ,s first dose, 16 hours after the fourth dose, and 1 to 4 hours after the fifth dose.
The equivalent responsE; dose (El~2o) is estimated from the dose response relationship to be the dose producing a 20% peak reduction in IOP.
Tables 7: Monkey lop Response Compound ED2o (N9) PGF2a Isopropyl Ester 0.4 6 0.3 l7iscussion:
As can be seen in Table 7, above, compound 6, the 13,14-dihydro analogue of fluprostenol was quite potent in the monkey IOP model, producing a 20%
reduction at 0.3 Ng. This was even more potent than the standard compound, 3o IPGF2a isopropyl ester. ', r The following Formulations 1-8 are representative pharmaceutical compositions of the invention for topical ring of intraocular pressure.
use in lowe Each of Formulations 1 through 8 may be formulated in accordance with procedures known to those skilled in the art.
FORMULATION ~
,o Ingredient Amount ~wt/4) Cloprostenol isopropyl ester 0.002 (Table 2, Compound A) Dextran 70 0.1 ,5 Hydroxypropyl methylcellulose 0.3 Sodium Chloride 0.77 Potassium chloride 0.12 Disodium EDTA (Edetate 0.05 disodium) 2o Benzalkonium chloride 0.01 ', HCI andlor NaOH pH 7.2 - 7.5 Purified water q.s. to 100%
~a ~A '~ , ~, _ _ ~.' .
Ingredient Amount (wt°/p) Cloprostenol, t butyl ester 0.01 s Monobasic sodium phosphate 0.05 Dibasic sodium phosphate 0.15 (anhydrous) Sodium chloride 0.75 Disodium EDTA (Edetate disodium) 0.01 ,o Benzalkonium chloride 0.02 Polysorbate 80 0.15 HCI and/or NaOH pH 7.3 - 7.4 ', Purified water q.s. to 100%
Ingredient: Amount {wt%) zo Cloprostenol, methyl eater 0.001 Dextran 70 0.1 Hydroxypropyl methylc~ellulose 0.5 Monobasic sodium phosphate 0.05 Dibasic sodium phosphate 0.15 2s (anhydrous) Sodium chloride 0.75 Disodium EDTA (Edeta.te disadium) 0.05 Benzalkonium chloride 0.01 NaOH and/or HCI pH 7.3 - 7.4 so Purified water q.s. to 100%
wr Ingredient Amount (wt%) Fluprostenol isopropyl ester 0.003 (Table 2, Compound B) ', Monobasic sodium phosphate 0.05 Dibasic sodium phosph<~te 0.15 (anhydrous) ,o Sodium chloride 0.75 Disodium EDTA (Edetate disodiurn) 0.05 Benzalkonium chloride 0.01 HCI and/or NaOH pH 7.3 ~ 7.4 Purified water q.s. to 100%
o ingredient Amount Qwt%j Compound 5 (Table 1 ) 0.002 Dextran 70 0.1 Hydroxypropyl methylcellulose 0.3 Sodium chloride 0.77 z5 Potassium chloride 0.12 Disodium EDTA 0.05 Benzalkonium chloride 0.01 HCI andlor NaOH , pH 7.2 - 7.5 Purified water q.s. to i 00%
,~s' G
E,r ,rr ...
Ingredient Amount (wt%) s Compound 6 (Table 1 ) 0.01 Monobasic sodium pho;>phate 0.05 Dibasic sodium phosphate 0.15 {anhydrous) Sodium chloride 0.75 ,o Disodium EDTA 0.01 Benzalkonium chloride 0.02 ';
Polysorbate 80 0.15 ', HCI and/or NaOH pH 7.3 - 7.4 Purified water q.s. to 100% ', ,5 0 Ingredient Amount (wt%) Compound 7 (Table 1 ) 0.001 Dextran 70 0.1 Hydroxypropyl methylce~llulose 0.5 Monobasic sodium phosphate 0.05 25 Dibasic sodium phosphate 0.15 ', (anhydrous) Sodium chloride 0.75 Disodium EDTA 0.05 Benzalkonium chloride 0.01 so NaOH andlor HCI pH 7.3 - 7.4 Purified water q.s. to 100%
~:
FC?RMUL_ATION :3 Ingredient Amount (wt%) ', s Compound 8 (Table 1 ) 0.003 Monobasic sodium pho:~phate 0.05 Dibasic sodium phosphate 0.15 (anhydrous) Sodium chloride 0.75 ,o Disodium EDTA 0.05 ', Benzalkonium chloride 0.01 HCI and/or NaOH pH 7.3 - 7.4 ', Purified water q.s. to 100%
,s The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential 2o characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.
Claims (54)
1. Use of a therapeutically effective amount of a compound of formula:
wherein:
R1 = H; C1-C12 straight-chain or branched alkyl;
C1-C12 straight-chain or branched acyl; C3-C8 cycloalkyl; a cationic salt moiety; or a pharmaceutically acceptable amine moiety;
R2, R3 = H, or C1-C5 straight-chain or branched alkyl;
or R2 and R3 taken together may represent O;
X = O, S, or CH2;
represents any combination of a single bond, or a cis or trans double bond for the alpha (upper) chain; and a single bond or trans double bond for the omega (lower) chain;
R9 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl;
R11 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl;
Y = O; or H and OR15 in either configuration wherein R15 - H, C1-C15 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl; and Z = C1 or CF3;
with the proviso that when R2 and R3 taken together represent O, then R1 .noteq. H; cationic salt moiety; C1-C12 straight-chain or branched acyl; and when R2 = R3 = H, then R1 .noteq. a cationic salt moiety or a pharmaceutically acceptable amine moiety; and with the further proviso that the following compound be excluded:
cyclopentaneheptanol-5-cis-2-(3-.alpha.hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3,5 dihydroxy, [1.alpha., 2.beta., 3.alpha., 5.alpha.], for the treatment of glaucoma and ocular hypertension.
wherein:
R1 = H; C1-C12 straight-chain or branched alkyl;
C1-C12 straight-chain or branched acyl; C3-C8 cycloalkyl; a cationic salt moiety; or a pharmaceutically acceptable amine moiety;
R2, R3 = H, or C1-C5 straight-chain or branched alkyl;
or R2 and R3 taken together may represent O;
X = O, S, or CH2;
represents any combination of a single bond, or a cis or trans double bond for the alpha (upper) chain; and a single bond or trans double bond for the omega (lower) chain;
R9 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl;
R11 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl;
Y = O; or H and OR15 in either configuration wherein R15 - H, C1-C15 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl; and Z = C1 or CF3;
with the proviso that when R2 and R3 taken together represent O, then R1 .noteq. H; cationic salt moiety; C1-C12 straight-chain or branched acyl; and when R2 = R3 = H, then R1 .noteq. a cationic salt moiety or a pharmaceutically acceptable amine moiety; and with the further proviso that the following compound be excluded:
cyclopentaneheptanol-5-cis-2-(3-.alpha.hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3,5 dihydroxy, [1.alpha., 2.beta., 3.alpha., 5.alpha.], for the treatment of glaucoma and ocular hypertension.
2. The use of claim 1, wherein: R2 =R3 =H, or R2 and R3 taken together represent O; X = O or CH2; R9 = R11 =
H; Y = H and OR15; and R15 = H.
H; Y = H and OR15; and R15 = H.
3. The use of claim 2, wherein: R1 - C1-C12 straight chain or branched alkyl; and R2 and R3 taken together represent O.
4. The use of claim 3, wherein the compound of formula (IV) is selected from the group consisting of 3-oxacloprostenol, 13,14-dihydrofluprostenol, and their pharma-ceutically acceptable esters and salts.
5. The use of claim 2, wherein: R1 = H or C1-C12 straight chain or branched acyl; and R2 = R3 =H.
6. The use of claim 5, wherein the compound of formula (IV) is selected from the group consisting of cloprostenol-1-ol and 13,14-dihydrocloprostenol-1-ol pivaloate.
7. The use of claim 2, wherein R2 and R3 taken together represent O; and X = CH2.
8. The use of claim 7, wherein: R1 = C1-C6 straight-chain or branched alkyl; or a pharmaceutically acceptable amine moiety.
9. The use of claim 8, wherein the compound of formula (IV) is selected from the group consisting of the pharmaceutically acceptable esters of cloprostenol and fluprostenol.
10. The use of claim 9, wherein the compound of formula (IV) is selected from the group consisting of the pharmaceutically acceptable esters of cloprostenol.
11. The use of claim 10, wherein the compound of formula (IV) is cloprostenol isopropyl ester.
12. The use of claim 9, wherein the compound of formula (IV) is selected from the group consisting of the pharmaceutically acceptable esters of fluprostenol.
13. The use of any one of claims 1 to 12, wherein said therapeutically effective amount of the compound is between 0.01 and 1000 µg/eye.
14. The use of claim 13, wherein the therapeu-tically effective amount is between 0.01 and 100 µg/eye.
15. The use of claim 14, wherein the therapeu-tically effective between 0.05 and 10 µ,g/eye.
16. A topical ophthalmic composition for the treatment of glaucoma and ocular hypertension comprising a therapeutically effective amount of a compound of formula:
wherein:
R1 = H; C1-C12 straight-chain or branched alkyl;
C1-C12 straight-chain or branched acyl; C3-C8 cycloalkyl; a cationic salt moiety; or a pharmaceutically acceptable amine moiety;
R2, R3 - H, or C1-C5 straight-chain or branched alkyl;
or R2 and R3 taken together represent O; with the proviso that if R2 and R3 taken together = O, then R1 .noteq. H or a cationic salt moiety;
and X = O, S, or CH2;
represents any combination of a single bond, or a cis or trans double bond for the alpha (upper) chain; and a single bond or trans double bond for the omega (lower) chain;
R9 - H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl;
R11 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl;
Y = O; or H and OR15 in either configuration wherein R15 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl; and Z = Cl or CF3;
with the proviso that when R2 and R3 taken together represent O, them R1 .noteq. C1-C12 straight-chain or branched acyl; and when R2 = R3 = H, then R1 .noteq. a cationic salt moiety; and with the further proviso that the following compound be excluded:
cyclopentaneheptanol-5-cis-2-(3-.alpha.hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3,5 dihydroxy, [1.alpha., 2.beta., 3.alpha., 5.alpha.]..
wherein:
R1 = H; C1-C12 straight-chain or branched alkyl;
C1-C12 straight-chain or branched acyl; C3-C8 cycloalkyl; a cationic salt moiety; or a pharmaceutically acceptable amine moiety;
R2, R3 - H, or C1-C5 straight-chain or branched alkyl;
or R2 and R3 taken together represent O; with the proviso that if R2 and R3 taken together = O, then R1 .noteq. H or a cationic salt moiety;
and X = O, S, or CH2;
represents any combination of a single bond, or a cis or trans double bond for the alpha (upper) chain; and a single bond or trans double bond for the omega (lower) chain;
R9 - H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl;
R11 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl;
Y = O; or H and OR15 in either configuration wherein R15 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl; and Z = Cl or CF3;
with the proviso that when R2 and R3 taken together represent O, them R1 .noteq. C1-C12 straight-chain or branched acyl; and when R2 = R3 = H, then R1 .noteq. a cationic salt moiety; and with the further proviso that the following compound be excluded:
cyclopentaneheptanol-5-cis-2-(3-.alpha.hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3,5 dihydroxy, [1.alpha., 2.beta., 3.alpha., 5.alpha.]..
17. The composition of claim 16, wherein: R2 - R3 = H, or R2 and R3 taken together represent O; X = O or CH2;
R9 = R11 = H; Y = H and OR15; and R15 - H.
R9 = R11 = H; Y = H and OR15; and R15 - H.
18. The composition of claim 17, wherein: R1 =
C1-C12 straight chain or branched alkyl; and R2 and R3 taken together represent O.
C1-C12 straight chain or branched alkyl; and R2 and R3 taken together represent O.
19. The composition of claim 18, wherein the compound for formula (IV) is selected from the group consisting of 3-oxacloprostenol, 13,14-dihydrofluprostenol, and their pharmaceutically acceptable esters and salts.
20. The composition of claim 17, wherein: R1 = H
or C1-C12 straight chain or branched aryl; and R2 = R3 = H.
or C1-C12 straight chain or branched aryl; and R2 = R3 = H.
21. The composition of claim 20, wherein the compound of formula (IV) is selected from the group consisting of cloprostenol-1-ol and 13,14-dihydro-cloprostenol-1-ol pivaloate.
22. The composition of claim 17, wherein: R2 and R3 taken together represent O; and X = CH2.
23. The composition of claim 22, wherein: R1 =
C1-C6 straight-chain or branched alkyl; or a pharma-ceutically acceptable amine moiety.
C1-C6 straight-chain or branched alkyl; or a pharma-ceutically acceptable amine moiety.
24. The composition of claim 23, wherein the compound of formula (IV) is selected from the group consisting of the pharmaceutically acceptable esters of cloprostenol and fluprostenol.
25. The composition of claim 24, wherein the compound of formula (IV) is selected from the group consisting of the pharmaceutically acceptable esters of cloprostenol.
26. The composition of claim 25, wherein the compound of formula (IV) is cloprostenol isopropyl ester.
27. The composition of claim 24, wherein the compound of formula (IV) is selected from the group consisting of the pharmaceutically acceptable esters of fluprostenol.
28. The composition of any one of claims 16 to 27, wherein the concentration of the compound of formula (IV) is between 0.00003 and 3 wt%.
29. The composition of claim 28, wherein the concentration of the compound of formula (IV) is between 0.0003 and 0.3 wt%.
30. The composition of claim 29, wherein the concentration of the compound of formula (IV) is between 0.003 and 0.03 wt%.
31. A compound of formula:
wherein:
R1 = H; C1-C12 straight-chain or branched alkyl;
C1-C12 straight-chain or branched acyl; C3-C8 cycloalkyl; a cationic salt moiety; or a pharmaceutically acceptable amine moiety;
R2, R3 - H, or C1-C5 straight-chain or branched alkyl;
or R2 and R3 taken together may represent O;
X = O;
represents any combination of a single bond, or a cis or trans double bond for the alpha (upper) chain; and a single bond or trans double bond for the omega (lower) chain;
R9 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl;
R11 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl;
Y = O; or H and OR15 in either configuration wherein R15 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl; and Z = Cl or CF3;
with the proviso that when R2 and R3 taken together represent O, then R1 .noteq. C1-C12 straight-chain or branched acyl; and when R2 = R3 = H, then R1 .noteq. a cationic salt moiety or a pharmaceutically acceptable amine moiety.
wherein:
R1 = H; C1-C12 straight-chain or branched alkyl;
C1-C12 straight-chain or branched acyl; C3-C8 cycloalkyl; a cationic salt moiety; or a pharmaceutically acceptable amine moiety;
R2, R3 - H, or C1-C5 straight-chain or branched alkyl;
or R2 and R3 taken together may represent O;
X = O;
represents any combination of a single bond, or a cis or trans double bond for the alpha (upper) chain; and a single bond or trans double bond for the omega (lower) chain;
R9 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl;
R11 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl;
Y = O; or H and OR15 in either configuration wherein R15 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl; and Z = Cl or CF3;
with the proviso that when R2 and R3 taken together represent O, then R1 .noteq. C1-C12 straight-chain or branched acyl; and when R2 = R3 = H, then R1 .noteq. a cationic salt moiety or a pharmaceutically acceptable amine moiety.
32. The compound of claim 31, having the formula:
33. Use of a therapeutically effective amount of a compound having the absolute stereochemical structure of the following formula (IV), and being substantially free of the enantiomer of said compound:
wherein:
R1 = H; C1-C12 straight-chain or branched alkyl;
C1-C12 straight-chain or branched acyl; C3-C8 cycloalkyl; a cationic salt moiety;
R2, R3 = H, or C1-C5 straight-chain or branched alkyl;
or R2 and R3 taken together may represent O;
X = O, S, or CH2;
represents any combination of a single bond, or a cis or traps double bond for the alpha (upper) chain; and a single bond or traps double bond for the omega (lower) chain;
R9 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl;
R11 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched aryl;
Y = O; or H and OR15 in either configuration wherein R15 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched aryl; and Z = Cl or CF3;
with the proviso that when R2 and R3 taken together represent O, then R1 .noteq. H; cationic salt moiety; C1-C12 straight-chain or branched acyl; and when R2 = R3 = H, then R1 .noteq. a cationic salt moiety;
with the further proviso that the following compound be excluded:
cyclopentaneheptanol-5-cis-2-(3-.alpha.hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3,5 dihydroxy, [1.alpha., 2.beta., 3.alpha., 5.alpha.], for the treatment of glaucoma and ocular hypertension.
wherein:
R1 = H; C1-C12 straight-chain or branched alkyl;
C1-C12 straight-chain or branched acyl; C3-C8 cycloalkyl; a cationic salt moiety;
R2, R3 = H, or C1-C5 straight-chain or branched alkyl;
or R2 and R3 taken together may represent O;
X = O, S, or CH2;
represents any combination of a single bond, or a cis or traps double bond for the alpha (upper) chain; and a single bond or traps double bond for the omega (lower) chain;
R9 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl;
R11 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched aryl;
Y = O; or H and OR15 in either configuration wherein R15 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched aryl; and Z = Cl or CF3;
with the proviso that when R2 and R3 taken together represent O, then R1 .noteq. H; cationic salt moiety; C1-C12 straight-chain or branched acyl; and when R2 = R3 = H, then R1 .noteq. a cationic salt moiety;
with the further proviso that the following compound be excluded:
cyclopentaneheptanol-5-cis-2-(3-.alpha.hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3,5 dihydroxy, [1.alpha., 2.beta., 3.alpha., 5.alpha.], for the treatment of glaucoma and ocular hypertension.
34. The use of claim 33, wherein for the compound (IV):
R2, R3 taken together represent O;
X = CH2;
represents a cis double bond for the alpha (upper) chain and a trans double bond for the omega (lower) chain;
R9 and R11 = H; and Y = OH in the alpha configuration and H in the beta configuration,
R2, R3 taken together represent O;
X = CH2;
represents a cis double bond for the alpha (upper) chain and a trans double bond for the omega (lower) chain;
R9 and R11 = H; and Y = OH in the alpha configuration and H in the beta configuration,
35. The use of claim 39, wherein for the compound (IV): Z = CF3.
36. The use of claim 33, wherein R2 = R3 = H, or R2 and R3 taken together represent O; X = O or CH2; R9 =
R11 = H; Y = H and OR15; and R15 = H.
R11 = H; Y = H and OR15; and R15 = H.
37. The use of claim 36, wherein: R1 = C1-C12 straight chain or branched alkyl or cationic salt moiety;
and R2 and R3 taken together represent O.
and R2 and R3 taken together represent O.
38. The use of claim 37, wherein the compound of formula (IV) is selected from the group consisting of 3-oxacloprostenol, 13, 14-dihydrofluprostenol, and their pharmaceutically acceptable esters and salts.
39. The use of claim 36, wherein: R1 = H or C1-C12 straight chain or branched acyl; and R2 = R3 = H.
40. The use of claim 39, wherein the compound formula (IV) is 13,14-dihydrocloprostenol-1-ol pivaloate.
41. The use of claim 33, wherein the therapeu-tically effective amount of the compound is between 0.01 and 1000 µg/eye.
42. The use of claim 41, wherein the therapeu-tically effective amount of the compound is between 0.1 and 100 µg/eye.
43. The use of claim 42, wherein the therapeu-tically effective amount of the compound is between 0.1 and µg/eye.
44. A topical ophthalmic composition for the treatment of glaucoma and ocular hypertension comprising an ophthalmically acceptable carrier and a therapeutically effective amount of a compound having the absolute stereochemical structure of the following formula (IV), and being substantially free of the enantiomer of said compound:
wherein R2 = H; C1-C12 straight-chain or branched alkyl;
C1-C12 straight-chain or branched acyl; C3-C8 cycloalkyl; a cationic salt moiety;
R2, R3 = H, or C1-C5 straight-chain or branched alkyl;
or R2 and R3 taken together may represent O;
X = O, S, or CH2;
represents any combination of a single bond, or a cis or trans double bond for the alpha (upper) chain; and a single bond or trans double bond for the omega (lower) chain;
R9 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl;
R11 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl;
Y = O; or H and OR15 in either configuration wherein R15 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched aryl; and Z = C1 or CF3;
with the proviso that when R2 and R3 taken together represent O, then R1 .noteq. C1-C12 straight-chain or branched acyl; and when R2 = R3 = H, then R1 .noteq. a cationic salt moiety; and with the further proviso that the following compound be excluded:
cyclopentaneheptanol-5-cis-2-(3-.alpha.hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3,5 dihydroxy, [1.alpha., 2.beta., 3.alpha., 5.alpha.].
wherein R2 = H; C1-C12 straight-chain or branched alkyl;
C1-C12 straight-chain or branched acyl; C3-C8 cycloalkyl; a cationic salt moiety;
R2, R3 = H, or C1-C5 straight-chain or branched alkyl;
or R2 and R3 taken together may represent O;
X = O, S, or CH2;
represents any combination of a single bond, or a cis or trans double bond for the alpha (upper) chain; and a single bond or trans double bond for the omega (lower) chain;
R9 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl;
R11 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched acyl;
Y = O; or H and OR15 in either configuration wherein R15 = H, C1-C10 straight-chain or branched alkyl, or C1-C10 straight-chain or branched aryl; and Z = C1 or CF3;
with the proviso that when R2 and R3 taken together represent O, then R1 .noteq. C1-C12 straight-chain or branched acyl; and when R2 = R3 = H, then R1 .noteq. a cationic salt moiety; and with the further proviso that the following compound be excluded:
cyclopentaneheptanol-5-cis-2-(3-.alpha.hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3,5 dihydroxy, [1.alpha., 2.beta., 3.alpha., 5.alpha.].
45. The composition of claim 44, wherein for the compound (IV):
R2, R3 taken together represent O;
X = CH2;
represents a cis double bond for the alpha (upper) chain and a trans double bond for the omege (lower) chain;
R9 and R11 = H; and Y = OH in the alpha configuration and H in the beta configuration.
R2, R3 taken together represent O;
X = CH2;
represents a cis double bond for the alpha (upper) chain and a trans double bond for the omege (lower) chain;
R9 and R11 = H; and Y = OH in the alpha configuration and H in the beta configuration.
46. The composition of claim 45, wherein for the compound (IV): Z = CF3.
47. The composition of claim 44, wherein: R2 = R3 = H, or R2 and R3 taken together represent O; X = O or CH2;
R9 = R11 = H; Y = H and OR15; and R15 = H.
R9 = R11 = H; Y = H and OR15; and R15 = H.
48. The composition of claim 47, wherein: R1 = H, C1-C12 straight chain or branched alkyl, or cationic salt moiety; and R2 and R3 taken together represent O.
49. The composition of claim 48, wherein the compound of formula (IV) is selected from the group consisting of 3-oxacloprostenol, 13,14-dihydrofluprostenol, and their pharmaceutically acceptable esters and salts.
50. The composition of claim 47, wherein: R1 = H
or C1-C12 straight chain or branched acyl; and R2 = R3 = H.
or C1-C12 straight chain or branched acyl; and R2 = R3 = H.
51. The composition of claim 50, wherein the compound of formula (IV) is 13,14-dihydrocloprostenol-1-ol pivaloate.
52. The composition of claim 44, wherein the concentration of the compound of formula (IV) is between 0.00003 and 3 wt%.
53. The composition of claim 52, wherein the concentration of the compound of formula (IV) is between 0.0003 and 0.3 wt%.
54. The composition of claim 53, wherein the concentration of the compound of formula (IV) is between 0.003 and 0.03 wt%.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/101,598 US5510383A (en) | 1993-08-03 | 1993-08-03 | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
US08/101,598 | 1993-08-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2129287A1 CA2129287A1 (en) | 1995-02-04 |
CA2129287C true CA2129287C (en) | 2002-05-14 |
Family
ID=22285486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002129287A Expired - Lifetime CA2129287C (en) | 1993-08-03 | 1994-08-02 | Use of cloprostenol, fluprostenol and their analogues to treat glaucoma and ocular hypertension |
Country Status (13)
Country | Link |
---|---|
US (3) | US5510383A (en) |
EP (3) | EP0639563B2 (en) |
JP (2) | JP2791544B2 (en) |
AT (1) | ATE286880T2 (en) |
AU (2) | AU690120B2 (en) |
CA (1) | CA2129287C (en) |
DE (1) | DE69434228T2 (en) |
DK (3) | DK0639563T4 (en) |
ES (3) | ES2235158T5 (en) |
HK (2) | HK1010717A1 (en) |
LU (2) | LU92058I2 (en) |
PT (3) | PT1920764E (en) |
SI (3) | SI1920764T2 (en) |
Families Citing this family (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5688819A (en) * | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US5972991A (en) * | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US6184250B1 (en) | 1993-08-03 | 2001-02-06 | Alcon Laboratories, Inc. | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension |
US5510383A (en) * | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
WO1997023225A1 (en) * | 1995-12-22 | 1997-07-03 | Alcon Laboratories, Inc. | Combinations of dp and fp type prostaglandins for lowering iop |
ATE221048T1 (en) * | 1996-09-17 | 2002-08-15 | Asahi Glass Co Ltd | FLUORINATED PROSTAGLAND DERIVATIVES AND MEDICATIONS |
WO1998019680A1 (en) * | 1996-11-01 | 1998-05-14 | Alcon Laboratories, Inc. | Use of a combination of carbonic anhydrase inhibitors and prostaglandins for treating glaucoma |
US6680339B2 (en) | 1996-11-12 | 2004-01-20 | Alcon Manufacturing, Ltd. | 15-fluoro prostaglandins as ocular hypotensives |
EP0938472B1 (en) | 1996-11-12 | 2001-06-27 | Alcon Laboratories, Inc. | 15-fluoro prostaglandins as ocular hypotensives |
AU5436198A (en) * | 1996-11-12 | 1998-06-03 | Alcon Laboratories, Inc. | 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension |
JP3480549B2 (en) * | 1996-12-26 | 2003-12-22 | 参天製薬株式会社 | Difluoroprostaglandin derivatives and uses thereof |
HUP0100638A3 (en) * | 1997-09-09 | 2002-12-28 | Procter & Gamble | Aromatic c16-c20-substituted tetrahydro prosraglandins useful as fp agonists |
CA2303801C (en) * | 1997-09-09 | 2005-05-10 | The Procter & Gamble Company | Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists |
US6066671A (en) | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
US6646001B2 (en) | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
PL350917A1 (en) | 1999-03-05 | 2003-02-10 | Procter & Gamble | C16 unsaturated fp-selective prostaglandins analogs |
US6214611B1 (en) | 1999-04-12 | 2001-04-10 | Chirotech Technology Limited | Process for the preparation of prostaglandin precursors |
GB9908326D0 (en) * | 1999-04-12 | 1999-06-09 | Chirotech Technology Ltd | Novel process intermediate for the synthesis of prostaglandins |
US6294679B1 (en) * | 1999-04-12 | 2001-09-25 | Chirotech Technology Limited | Intermediate for the synthesis of prostaglandins |
US6894175B1 (en) * | 1999-08-04 | 2005-05-17 | The Procter & Gamble Company | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use |
TWI290470B (en) | 1999-12-01 | 2007-12-01 | Sankyo Co | The composition for treating glaucoma |
AU2001228836A1 (en) * | 2000-01-28 | 2001-08-07 | Santen Pharmaceutical Co., Ltd. | Novel difluoroprostaglandin derivative |
JP2003531824A (en) | 2000-02-01 | 2003-10-28 | ケイマン ケミカル カムパニー,インク. | Internal 1,15-lactones of fluprostenol and related prostaglandin F2α analogs and their use in treating glaucoma and ocular hypertension |
US6956036B1 (en) | 2000-03-17 | 2005-10-18 | Alcon, Inc. | 6-hydroxy-indazole derivatives for treating glaucoma |
US7005443B1 (en) | 2000-03-17 | 2006-02-28 | Alcon, Inc. | 5-Hydroxy indazole derivatives for treating glaucoma |
US6927233B1 (en) | 2000-03-17 | 2005-08-09 | Alcon, Inc. | 5ht2 agonists for controlling IOP and treating glaucoma |
US20030119846A1 (en) * | 2000-03-17 | 2003-06-26 | Collier Jr Robert J. | Compounds with 5-ht activity useful for controlling visual field loss |
US6660870B1 (en) | 2000-03-17 | 2003-12-09 | Alcon, Inc. | 2-acylaminobenzimidazole derivatives for treating glaucoma |
US6806285B1 (en) | 2000-03-17 | 2004-10-19 | Alcon, Inc. | 5-Hydroxyl indole derivatives for treating glaucoma |
US7012090B1 (en) | 2000-03-17 | 2006-03-14 | Alcon, Inc. | Pyranoindoles for treating glaucoma |
US20020013294A1 (en) * | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US20020037914A1 (en) * | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
US20020146439A1 (en) * | 2000-03-31 | 2002-10-10 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
PE20020146A1 (en) * | 2000-07-13 | 2002-03-31 | Upjohn Co | OPHTHALMIC FORMULATION INCLUDING A CYCLOOXYGENASE-2 (COX-2) INHIBITOR |
WO2004098807A1 (en) * | 2000-11-21 | 2004-11-18 | Barsplice Products, Inc. | Method of making steel couplers for joining concrete reinforcing bars |
US20050171054A1 (en) * | 2001-01-19 | 2005-08-04 | Helge Rask-Andersen | Novel method and composition for local treatment of meniere's disease, tinnitus and/or hearing loss |
SE0100158D0 (en) * | 2001-01-19 | 2001-01-19 | Synphora Ab | Novel method and composition for local treatment of Meniere's disease and tinnitus |
WO2002085248A2 (en) * | 2001-04-23 | 2002-10-31 | Board Of Regents The University Of Texas System | Prostanoids augment ocular drug penetration |
US20030212107A1 (en) * | 2001-05-10 | 2003-11-13 | Kapin Michael A. | R-reliprodil for treating glaucoma |
GB0112699D0 (en) * | 2001-05-24 | 2001-07-18 | Resolution Chemicals Ltd | Process for the preparation of prostglandins and analogues thereof |
JP2004532887A (en) * | 2001-06-01 | 2004-10-28 | アルコン,インコーポレイテッド | Novel fused indazoles and their use in treating indole and glaucoma |
ATE318821T1 (en) * | 2001-06-01 | 2006-03-15 | Alcon Inc | PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT |
CN1512879A (en) * | 2001-06-01 | 2004-07-14 | �Ƹ��� | Novel arylaminopropane analogues and their use for treatment of glaucoma |
US6884816B2 (en) * | 2001-08-31 | 2005-04-26 | Alcon, Inc. | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma |
US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
US7351404B2 (en) * | 2002-02-04 | 2008-04-01 | Allergan, Inc. | Method of enhancing hair growth |
US8758733B2 (en) | 2002-02-04 | 2014-06-24 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
US9216183B2 (en) | 2002-02-04 | 2015-12-22 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
US20040110776A1 (en) * | 2002-02-22 | 2004-06-10 | Iok-Hou Pang | Use of propentofylline to control intraocular pressure |
DE60326226D1 (en) * | 2002-03-21 | 2009-04-02 | Cayman Chemical Co | PROSTAGLANDIN F2 ALPHA ANALOGUE IN COMBINATION WITH AN ANTIMICROBIAL AGENT FOR THE TREATMENT OF GLAUCOMA |
AU2003233729B2 (en) | 2002-06-06 | 2007-10-04 | Merck Frosst Canada Ltd | 1,5-distributed pyrrolid-2-one derivatives for use as EP4 receptor agonists in the treatment of eye diseases such as glaucoma |
US20060258726A1 (en) * | 2002-06-06 | 2006-11-16 | Xavier Billot | 1,5-Disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases |
US6864282B2 (en) * | 2002-08-05 | 2005-03-08 | Allergan, Inc. | 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma |
EP1545517A1 (en) * | 2002-08-28 | 2005-06-29 | Merck Frosst Canada & Co. | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma |
ATE546143T1 (en) * | 2002-08-29 | 2012-03-15 | Santen Pharmaceutical Co Ltd | AGENT FOR TREATING GLAUCOMA WITH A RHO-KINASE INHIBITOR AND PROSTAGLANDINS |
AU2003262931B2 (en) * | 2002-08-30 | 2008-06-26 | Alcon, Inc. | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma |
WO2004037786A2 (en) * | 2002-10-25 | 2004-05-06 | Merck Frosst Canada & Co. | 2-pyrrolidones as ep4 receptor agonists |
US7196082B2 (en) * | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
CA2505127A1 (en) * | 2002-11-08 | 2004-05-27 | James B. Doherty | Ophthalmic compositions for treating ocular hypertension |
US20080004311A1 (en) * | 2002-11-12 | 2008-01-03 | Alcon, Inc. | Histone deacetylase inhibitors for treating degenerative diseases of the eye |
RU2324483C2 (en) * | 2002-11-12 | 2008-05-20 | Алькон, Инк. | Inhibitors of hystone deacetylase for treatment of degenerative eye diseases |
JP4314433B2 (en) | 2002-11-18 | 2009-08-19 | 参天製薬株式会社 | Glaucoma treatment agent comprising Rho kinase inhibitor and β-blocker |
US7053085B2 (en) | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
MXPA05005937A (en) * | 2002-12-06 | 2005-08-18 | Alcon Inc | Histone deacetylase inhibitors for treating degenerative diseases of the eye. |
JP2006511556A (en) * | 2002-12-13 | 2006-04-06 | アルコン,インコーポレイテッド | Novel benzopyran analogs and their use for the treatment of glaucoma |
AR043161A1 (en) * | 2003-02-14 | 2005-07-20 | Sucampo Pharmaceuticals Inc | OPHTHALM COMPOSITION TO TREAT OCULAR HYPERTENSION AND GLAUCOMA |
EP1646614A4 (en) * | 2003-07-01 | 2008-09-10 | Merck & Co Inc | Ophthalmic compositions for treating ocular hypertension |
US20050119262A1 (en) * | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
CA2537119A1 (en) * | 2003-09-02 | 2005-03-10 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
EP1663987B1 (en) * | 2003-09-04 | 2009-03-18 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
CN1842335A (en) * | 2003-09-04 | 2006-10-04 | 默克公司 | Ophthalmic compositions for treating ocular hypertension |
JP2007504198A (en) * | 2003-09-05 | 2007-03-01 | ノバルティス アクチエンゲゼルシャフト | Composition comprising benzo [g] quinoline derivative and prostaglandin derivative |
WO2005044276A1 (en) * | 2003-11-07 | 2005-05-19 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical composition containing prostaglandin |
US7476687B2 (en) * | 2003-11-26 | 2009-01-13 | Alcon, Inc. | Substituted furo[2,3-g]indazoles for the treatment of glaucoma |
US7338972B1 (en) | 2003-12-15 | 2008-03-04 | Alcon, Inc. | Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma |
WO2005058911A2 (en) * | 2003-12-15 | 2005-06-30 | Alcon, Inc. | Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma |
US7129257B1 (en) | 2003-12-15 | 2006-10-31 | Alcon, Inc. | Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma |
GB0329620D0 (en) * | 2003-12-22 | 2004-01-28 | Pharmagene Lab Ltd | EP2 receptor agonists |
JP2005263792A (en) * | 2004-02-19 | 2005-09-29 | Santen Pharmaceut Co Ltd | Clear latanoprost eye lotion |
WO2005079809A1 (en) * | 2004-02-19 | 2005-09-01 | Santen Pharmaceutical Co., Ltd. | Transparent latanoprost eye drops |
DE602005008935D1 (en) * | 2004-04-26 | 2008-09-25 | Alcon Inc | STATINE FOR THE TREATMENT OF OCCULAR HYPERTONIA AND GLAUCOMA |
CA2574078A1 (en) | 2004-07-20 | 2006-02-23 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
US20080097108A1 (en) * | 2004-10-13 | 2008-04-24 | Ying-Duo Gao | Ophthalmic Compositions for Treating Ocular Hypertension |
JP2008515982A (en) * | 2004-10-13 | 2008-05-15 | メルク エンド カムパニー インコーポレーテッド | Ophthalmic composition for treating ocular hypertension |
DE602004017477D1 (en) * | 2004-11-09 | 2008-12-11 | Novagali Pharma Sa | Oil-in-water emulsion with low concentration of cationic agent and positive zeta potential |
US7425572B2 (en) * | 2004-12-08 | 2008-09-16 | Alcon, Inc. | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma |
ATE465986T1 (en) * | 2005-01-14 | 2010-05-15 | Allergan Inc | SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES FOR THE TREATMENT OF EYE HYPERTENSION |
GB0501192D0 (en) * | 2005-01-20 | 2005-03-02 | Resolution Chemicals Ltd | Stable prostaglandin-containing compositions |
US7851504B2 (en) | 2005-03-16 | 2010-12-14 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
WO2010102078A1 (en) | 2009-03-04 | 2010-09-10 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
CN102293774A (en) | 2005-03-31 | 2011-12-28 | 旭硝子株式会社 | Application of prostaglandin f2 alpha derivative |
RU2392938C2 (en) | 2005-04-13 | 2010-06-27 | Убе Индастриз, Лтд | Protective agent for neural retina cells containing indazole derivatives as active ingredient |
WO2007002670A2 (en) * | 2005-06-28 | 2007-01-04 | Bausch & Lomb Incorporated | Method of lowering intraocular pressure |
US20090270395A1 (en) * | 2005-08-03 | 2009-10-29 | John Colucci | EP4 Receptor Agonist, Compositions and Methods Thereof |
TW200744567A (en) * | 2005-09-23 | 2007-12-16 | Alcon Inc | Phenylethylamine analogs and their use for treating glaucoma |
EP1810967B1 (en) | 2006-01-18 | 2014-07-30 | Chirogate International Inc. | Processes and intermediates for the preparations of prostaglandins |
US20070219272A1 (en) * | 2006-02-06 | 2007-09-20 | Johan Stjernschantz | Novel method and compositions for treatment of tinnitus |
CN103768070A (en) * | 2006-03-13 | 2014-05-07 | 株式会社·R-技术上野 | Aqueous composition |
AU2007227664A1 (en) * | 2006-03-13 | 2007-09-27 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
US7666912B2 (en) | 2006-03-23 | 2010-02-23 | Massachusetts Eye And Ear Infirmary | Compositions and methods for reducing body fat |
CA2653903A1 (en) * | 2006-06-12 | 2007-12-21 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
UY30883A1 (en) | 2007-01-31 | 2008-05-31 | Alcon Res | PUNCTURAL PLUGS AND METHODS OF RELEASE OF THERAPEUTIC AGENTS |
AU2008220104B2 (en) | 2007-02-28 | 2012-09-27 | Asahi Kasei Pharma Corporation | Sulfonamide derivative |
US20090018204A1 (en) * | 2007-07-13 | 2009-01-15 | Brinkenhoff Michael C | Composition and method for enhancing hair growth |
AU2009246573B2 (en) * | 2008-05-15 | 2014-04-24 | Allergan, Inc. | Therapeutic substituted cyclopentanes |
US20080275118A1 (en) * | 2008-06-12 | 2008-11-06 | Shaw Mari M | Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US8722739B2 (en) * | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
US8623918B2 (en) | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
EP2349242B1 (en) | 2008-10-29 | 2018-12-05 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
US20100204335A1 (en) * | 2008-12-01 | 2010-08-12 | Allergan, Inc. | Kit and composition for eyelash growth |
US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
WO2010112615A1 (en) | 2009-04-03 | 2010-10-07 | Dsm Ip Assets B.V. | Lysine derivatives functionalised with lipids |
CA2929545C (en) | 2009-05-01 | 2019-04-09 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
CA2773597A1 (en) | 2009-09-17 | 2011-03-24 | Senju Pharmaceutical Co., Ltd. | Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin |
US9149484B2 (en) | 2009-11-09 | 2015-10-06 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
BR122017013201B1 (en) | 2009-11-09 | 2018-05-15 | Allergan, Inc. | COMPOSITION FOR STIMULATION OF HAIR GROWTH |
EP2389939A1 (en) | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
US9522153B2 (en) | 2009-12-22 | 2016-12-20 | Allergan, Inc. | Compositions and methods for lowering intraocular pressure |
CN103079535B (en) | 2010-08-02 | 2016-10-12 | Ac专利控股公司 | For strengthening the compositions of hair, method and test kit |
WO2012078649A1 (en) | 2010-12-06 | 2012-06-14 | Follica, Inc. | Methods for treating baldness and promoting hair growth |
US9089579B2 (en) | 2011-01-19 | 2015-07-28 | Topokine Therapeutics, Inc. | Methods and compositions for treating metabolic syndrome |
US8859616B2 (en) | 2011-01-21 | 2014-10-14 | Allergan, Inc. | Compounds and methods for enhancing hair growth |
TW201729813A (en) | 2011-02-04 | 2017-09-01 | Kowa Co Ltd | Drug therapy for preventing or treating glaucoma |
US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
HU231203B1 (en) | 2011-12-21 | 2021-10-28 | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. | Novel process for the preparation of travoprost |
WO2013133730A1 (en) * | 2012-03-09 | 2013-09-12 | Instytut Farmaceutyczny | PROCESS FOR PREPARATION OF PROSTAGLANDIN F2α ANALOGUES |
CA2869676C (en) | 2012-11-21 | 2015-06-23 | Topokine Therapeutics, Inc. | Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat |
HU230744B1 (en) | 2012-11-30 | 2018-01-29 | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. | Novel process for preparing travoprost |
EP3461484B9 (en) | 2013-03-15 | 2021-06-09 | Aerie Pharmaceuticals, Inc. | Dimesylate salts of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl, their combinations with prostaglandins and the use thereof in the treatment of ocular disorders |
NO2753788T3 (en) | 2013-05-10 | 2018-06-16 | ||
WO2014186504A1 (en) | 2013-05-15 | 2014-11-20 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
EP3091985A4 (en) | 2014-01-10 | 2017-11-29 | Manistee Partners LLC | Treatment of migraines |
HU231214B1 (en) | 2014-03-13 | 2021-11-29 | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. | New process for preparing high purity prostaglandins |
US10188661B2 (en) | 2014-06-27 | 2019-01-29 | Topokine Therapeutics, Inc. | Topical dosage regimen |
WO2016061370A1 (en) * | 2014-10-15 | 2016-04-21 | Novartis Ag | Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension |
EA034839B1 (en) | 2014-10-20 | 2020-03-26 | Сентисс Фарма Прайвет Лимитед | Ophthalmic solution |
CA2968926C (en) | 2014-11-25 | 2023-01-17 | Izhar Halahmi | Compositions and methods for delivering a bio-active agent or bio-active agents |
US10280138B2 (en) | 2015-03-31 | 2019-05-07 | Nicox S.A. | Nitric oxide donating derivatives of fluprostenol |
JP2018534018A (en) | 2015-09-27 | 2018-11-22 | フォリカ, インコーポレーテッドFollica, Inc. | Needle insertion device and drug applicator |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
DE102016110381A1 (en) * | 2016-06-06 | 2017-12-07 | Edwin Kohl | Cosmetic composition, in particular for promoting hair growth |
US11478437B2 (en) | 2016-07-05 | 2022-10-25 | Jenivision Inc. | Formulations for hair growth |
BR112019003945A2 (en) | 2016-08-31 | 2019-05-21 | Aerie Pharmaceuticals, Inc. | ophthalmic compositions |
CN110506037A (en) | 2017-03-31 | 2019-11-26 | 爱瑞制药公司 | Aryl cyclopropyl-amino-isoquinolin amide compound |
AU2019337703B2 (en) | 2018-09-14 | 2023-02-02 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE37602B1 (en) * | 1971-05-11 | 1977-08-31 | Ici Ltd | Cyclopentane derivatives |
GB1350971A (en) * | 1971-05-11 | 1974-04-24 | Imp Chemi Als Ind Ltd | Cyclopentane derivatives |
GB1451798A (en) * | 1973-08-02 | 1976-10-06 | Ici Ltd | Prostanoic acid derivatives |
GB1486832A (en) * | 1974-08-05 | 1977-09-28 | Ici Ltd | Prostanoic acid derivatives |
DE2523676A1 (en) * | 1975-05-26 | 1976-12-16 | Schering Ag | Esters of 1-hydroxy prostaglandins - with stronger, more selective and longer lasting activities |
US4159343A (en) * | 1975-05-26 | 1979-06-26 | Schering Aktiengesellschaft | Prostane derivatives |
NL7605381A (en) * | 1975-05-26 | 1976-11-30 | Schering Ag | METHOD FOR PREPARING PROSTANE DERIVES AND METHOD FOR PREPARING A MEDICINAL PRODUCT WITH PROSTAGLANDIN ACTION. |
US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
EP0308135B1 (en) * | 1987-09-18 | 1992-11-19 | R-Tech Ueno Ltd. | Ocular hypotensive agents |
JP2597629B2 (en) * | 1988-02-26 | 1997-04-09 | 株式会社 上野製薬応用研究所 | Stabilization of 13,14-dihydro-15-ketoprostaglandins |
US5565492A (en) * | 1988-07-18 | 1996-10-15 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
US5173507A (en) * | 1988-07-18 | 1992-12-22 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
ES2186670T3 (en) * | 1988-09-06 | 2003-05-16 | Pharmacia Ab | PROSTAGLANDIN DERIVATIVES FOR THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION. |
ATE162074T1 (en) * | 1988-10-01 | 1998-01-15 | R Tech Ueno Ltd | OCULAR HYPOTENSIVE AGENTS |
CA2031469A1 (en) * | 1989-12-28 | 1991-06-29 | Larry A. Wheeler | Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension |
HU212570B (en) † | 1991-06-24 | 1996-08-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester |
US5288754A (en) * | 1992-02-04 | 1994-02-22 | Allergan, Inc. | Polar C-1 esters of prostaglandins |
US5352708A (en) * | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
DE69311361T2 (en) * | 1992-10-13 | 1998-01-08 | Alcon Lab Inc | COMPOSITIONS FOR TREATING GLAUCOMA CONTAINING PROSTAGLANDINES AND CLONIDINE DERIVATIVES |
AU665287B2 (en) | 1992-12-21 | 1995-12-21 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
US5510383A (en) * | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
-
1993
- 1993-08-03 US US08/101,598 patent/US5510383A/en not_active Expired - Lifetime
-
1994
- 1994-07-28 AU AU68779/94A patent/AU690120B2/en not_active Expired - Fee Related
- 1994-08-02 CA CA002129287A patent/CA2129287C/en not_active Expired - Lifetime
- 1994-08-03 EP EP94305752.1A patent/EP0639563B2/en not_active Expired - Lifetime
- 1994-08-03 ES ES94305752T patent/ES2235158T5/en not_active Expired - Lifetime
- 1994-08-03 DK DK94305752.1T patent/DK0639563T4/en active
- 1994-08-03 EP EP08100474.9A patent/EP1920764B2/en not_active Expired - Lifetime
- 1994-08-03 DK DK08100474.9T patent/DK1920764T4/en active
- 1994-08-03 DK DK04077870.6T patent/DK1514548T3/en active
- 1994-08-03 PT PT08100474T patent/PT1920764E/en unknown
- 1994-08-03 PT PT40778706T patent/PT1514548E/en unknown
- 1994-08-03 ES ES04077870.6T patent/ES2458493T3/en not_active Expired - Lifetime
- 1994-08-03 SI SI9430492T patent/SI1920764T2/en unknown
- 1994-08-03 DE DE69434228T patent/DE69434228T2/en not_active Expired - Lifetime
- 1994-08-03 EP EP04077870.6A patent/EP1514548B1/en not_active Revoked
- 1994-08-03 SI SI9430472T patent/SI0639563T1/en unknown
- 1994-08-03 ES ES08100474T patent/ES2385267T5/en not_active Expired - Lifetime
- 1994-08-03 AT AT94305752T patent/ATE286880T2/en active
- 1994-08-03 JP JP6202705A patent/JP2791544B2/en not_active Expired - Lifetime
- 1994-08-03 SI SI9430493T patent/SI1514548T1/en unknown
- 1994-08-03 PT PT94305752T patent/PT639563E/en unknown
-
1996
- 1996-12-18 US US08/769,293 patent/US5665773A/en not_active Expired - Lifetime
-
1997
- 1997-08-21 US US08/917,795 patent/US5889052A/en not_active Expired - Lifetime
- 1997-12-24 JP JP36594697A patent/JP3650258B2/en not_active Expired - Lifetime
-
1998
- 1998-07-23 AU AU77488/98A patent/AU704670B2/en not_active Expired
- 1998-11-05 HK HK98111753A patent/HK1010717A1/en not_active IP Right Cessation
-
2005
- 2005-04-13 HK HK05103113.1A patent/HK1072716A1/en unknown
-
2012
- 2012-08-08 LU LU92058C patent/LU92058I2/en unknown
-
2014
- 2014-07-25 LU LU92509C patent/LU92509I2/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2129287C (en) | Use of cloprostenol, fluprostenol and their analogues to treat glaucoma and ocular hypertension | |
US6723748B2 (en) | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension | |
KR100526282B1 (en) | Difluoroprostaglandin derivatives and their use | |
EP0783308B1 (en) | Use of 9-deoxy prostaglandin derivatives to treat glaucoma | |
US7674921B2 (en) | Internal 1,15-lactones of fluprostenol and related prostaglandin F2α analogs and their use in the treatment of glaucoma and intraocular hypertension | |
US6169111B1 (en) | Conformationally rigid aryl prostaglandins for use in glaucoma therapy | |
US6353000B1 (en) | 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension | |
US6172109B1 (en) | 13-Thia prostaglandins for use in glaucoma therapy | |
US6344581B1 (en) | Method of prostaglandin synthesis | |
WO1995026729A1 (en) | New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | |
US6680339B2 (en) | 15-fluoro prostaglandins as ocular hypotensives | |
IE902722A1 (en) | INTRAOCULAR PRESSURE REDUCING 9, 11-Diacyl Prostaglandins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20140804 |